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ABSTRACT 
 
KATE CLOUSE: Patient retention at key milestones after HIV diagnosis at a primary 
healthcare clinic offering early antiretroviral therapy initiation in Johannesburg, South Africa 
(Under the direction of Audrey Pettifor) 
 
 
A significant challenge to the impact of South Africa’s national ART program is poor 
patient retention. We report retention in early HIV care among patients at Witkoppen Health 
and Welfare Centre in Johannesburg, South Africa, using data obtained via file review and 
electronically. We look first at multiple stages of early HIV care among newly-diagnosed, 
non-pregnant adults (N=842). Retention from HIV testing to CD4 staging was 69.8% (95%CI 
66.7-72.9%). For patients initially ART-ineligible (n=221), 57.4% (95%CI 49.5-65.0%) 
returned for a repeat CD4 within 12 months. Among those ART-eligible (n=589), 73.5% 
(95%CI 69.0-77.6%) were retained between CD4 staging and ART initiation. Retention 
increased with time on ART, from 80.2% (95%CI 75.3-84.5%) at 6 months to 95.3% (95%CI 
91.7-97.6%) between 6-12 months. Cumulative retention from HIV diagnosis to 12 months 
on ART was 36.9% (95%CI 33.0-41.1%) for those ART-eligible and 43.0% (95%CI 36.4-
49.8%) from diagnosis to repeat CD4 testing within one year among those ART-ineligible.  
We examined loss to follow-up (LTFU) before and after delivery among pregnant 
women newly-diagnosed with HIV (N=273). Of 139 (51.3%) ART-eligible patients, 66.9% 
(95%CI 58.8-74.3%) initiated ART prior to delivery and overall, 40.5% (32.3-49.0%) were 
cumulative retained through six months on ART. Of those ART-ineligible at HIV diagnosis, 
only 21.1% (95%CI 14.6-29.0%) were retained through a repeat CD4 test after delivery. 
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LTFU (≥1 month late) before delivery was 20.5% (95%CI 16.0-25.6%) and, among those still 
in care, 47.9% (95%CI 41.2-54.6%) within six months after delivery.  
The study clinic has offered ART initiation at CD4 ≤350 cells/µl since 2010. We 
compared 12-month patient outcomes for those who presented and initiated ART at 
baseline CD4 values ≤200 versus 201-350 cells/µl (N=1430). Among men and non-pregnant 
women, initiating at 201-350 cells/µl was associated with 26-42% reduced LTFU (≥3 months 
late) compared to those initiating at ≤200. We found no CD4 effect among pregnant women.  
As countries expand HIV testing and ART programs, success will depend on linkage 
to and retention in care, especially during the period prior to ART initiation. Our findings 
highlight the additional challenge of continuity of care among HIV-positive pregnant women 
and adults ineligible for ART.  
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CHAPTER 1 
INTRODUCTION AND REVIEW OF THE LITERATURE 
 
 Sub-Saharan Africa is the region of the world hardest hit by the HIV/AIDS pandemic. 
Of the 33.3 million people living with HIV/AIDS in 2009, 22.5 million (68%) are in sub-
Saharan Africa, and the region is home to 72% of the world’s HIV/AIDS deaths.1 South 
Africa’s epidemic remains the world’s largest with 5.6 million people living with HIV in 2009, 
adult HIV prevalence estimated at 16.9%, and 410,000 estimated new infections in 2010.1-3   
South Africa also has the largest antiretroviral therapy (ART) program in the world.1 
The national ART program started in 2004 and has quickly grown in size with over 1.7 
million adults and children enrolled over the first seven years.4 This advancement has 
dramatically altered the health and quality of life of people living with HIV/AIDS. UNAIDS 
estimates that over 700,000 adult life-years were gained as a result of ART in South Africa 
through 2009.1  At the same time, the rapid scale-up of the national ART program has put 
tremendous pressure on the limited resources of a public health sector that is struggling to 
meet the immense need. It is estimated that only 52% of patients eligible for ART are 
currently on treatment.4 Despite the fact that 300,000 patients enroll in the South African 
ART program each year,5 an estimated 280,000 people died of AIDS in 2010, representing 
43% of the country’s total deaths.3 Moving forward, South Africa will need to expand its 
national ART program to meet the needs of more patients within a context of limited 
resources, while ensuring quality, sustainable care. 
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An enormous challenge to the existing South African ART program and current 
attempts to expand its impact is the large number of patients who either do not access care, 
or who leave care. Numerous barriers to initiating and remaining in care exist for HIV-
positive individuals, including psychological and social factors such as denial of disease 
status and severity,6 distrust of the healthcare system in terms of quality care and 
confidentiality,7-9 and disease stigma.2,6,7,9,10 
The “necessity-concerns” conceptual framework, which has been utilized in 
medication adherence research across a span of diseases,11,12 may accurately describe the 
considerations an individual faces when seeking HIV care and adhering to ART.13 This 
framework describes how patients’ perceived need for ART may be at odds with the clinical 
necessity, and explains how pre-existing beliefs about ART, such as fear of side effects, 
may dissuade eligible patients from accessing treatment. Similarly, low perceived need for 
ART among patients eligible for ART may predict both failure to initiate and adherence to 
ART. 13 While this framework, to our knowledge, has not been used among southern African 
populations, other researchers in the region have noted that patients who did not feel sick 
were less likely to access care or continue treatment.6,9 Others may prefer traditional 
medicine and healers to ART and clinics.6,8,9,14 
In addition to numerous psychological and social obstacles to accessing and 
remaining in care, structural barriers also may prevent patients from initiating or continuing 
care. At the healthcare facilities, these may include complex, disjointed systems of 
healthcare,10 lengthy queues,6,8 and limited operating hours that conflict with employment 
commitments.8  Furthermore, poverty and an inability to pay for transit fares and clinic fees 
limits individuals’ ability to access care.7-10,14 Lacking food to eat while taking ART also has 
been mentioned as a barrier in Southern Africa.9 Frequent migration and housing instability 
among low-income, highly-mobile populations in South Africa also may lead to interruptions 
in care.14,15 While the majority of research focuses on barriers to care, community 
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involvement, faith-based initiatives, and active tracing and home visits have been noted as 
facilitators of retention in care.16,17 
As a result of these barriers, HIV-positive patients in South Africa and other 
resource-limited countries are more likely to have advanced immunosuppression (i.e. lower 
CD4 counts) when starting ART, thus,  are more likely to be at increased risk of mortality, 
underscoring the urgency of initiating and retaining patients in care.18,19 Continuous 
engagement in care is particularly important for HIV patients since HIV requires lifelong 
treatment with high adherence as patients who stop and restart treatment increase their risk 
of drug resistance, treatment failure and ultimately, death.20,21  Two South Africa-based 
studies linked to the national death registry have estimated mortality among patients lost to 
care at 31% after one year and 36-44% after two years.22,23 Even patients who remain in 
care but missed multiple ART appointments within the first six months of initiation are at 
increased risk of poor CD4 responses and failure to achieve viral suppression.24 
Patient attrition refers to loss to care, which includes both patients who die and 
patients who are lost to follow-up (LTFU) (i.e. those who do not return to the clinic after a 
defined period of time). Patients can leave care at any point in their care, so dividing care up 
into meaningful periods over which to assess retention is necessary. Focusing specifically 
on the first year of HIV care (a time of high attrition), it is helpful to characterize retention in 
relation to key events in care. For those who test HIV-positive, blood must be collected and 
(in most cases) sent to an outside lab for CD4 testing, then the patient must return for 
results at a later visit, typically the visit following HIV diagnosis. For ART-eligible patients, 
adherence counseling is often required prior to treatment initiation. Patients who are 
ineligible for ART are to be enrolled in a wellness program with follow-up visits every six 
months for CD4 monitoring. Since there are multiple points in the process where patients 
may be lost to care, there are fewer patients at each step of the process, as shown in Figure 
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1. This loss of patients through consecutive time points is sometimes referred to as the “HIV 
treatment cascade.”25  
Figure 1. HIV-positive patient loss to care over time 
 
In recent years, quantifying the problem of patient attrition in care among HIV-
positive patients worldwide as well as within the public-sector in South Africa has begun to 
receive attention. Following the introduction of ART in the public-sector in South Africa in 
2004, research primarily focused on patient retention in care after treatment initiation. These 
studies now provide many years of data about patient retention in care following initiation 
(see Table A.1). A large (N=44,177) collaborative analysis of eight cohorts initiating ART 
across South Africa found that patient attrition increased with duration on treatment, and by 
36 months, 29% were LTFU.26 A review of 33 publications of cohorts in sub-Saharan African 
countries (N=226,307) found that ART programs lose about 25% of their patients within two 
years.27 In both analyses, younger patients and those who initiated with very low CD4 
counts were significantly more likely to be LTFU.  
Results of this research on program retention suggest that rates of LTFU and 
mortality are highest in the first year of HIV care.27-29 Thus, loss of patients during the 
earliest phases of HIV care – immediately after diagnosis and prior to ART initiation – is 
gaining research attention (see Table A.2) and several studies have described pre-ART loss 
within South Africa. Studies in Durban, Johannesburg and Cape Town have found that only 
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about half (45-63%) of newly-diagnosed patients complete CD4 staging (including results 
notification) within eight weeks to six months after testing HIV-positive.30-32 One study noted 
that CD4 testing was lowest (15%) among patients with a CD4 count >200 cells/µl.33   
Patients who are ineligible for ART based on CD4 testing must return for regular 
CD4 monitoring and eligibility assessment for ART. This is a particularly difficult period in 
which to retain patients, for patients with higher CD4 values may feel well and may not seek 
care, and facilities may prioritize sicker patients over the routine care of patients with higher 
CD4 counts. It is also difficult to measure retention among patients ineligible for ART 
because the defined end point – becoming eligible for ART based on CD4 testing – is 
unique to each individual patient and there is no time period for eligibility that is appropriate 
for all patients. Thus, studies on retention among ART-ineligible patients are few but indicate 
poor rates of repeat testing. In a Cape Town study, 46.3% of patients with CD4 >200 cells/µl 
returned for repeat CD4 testing during the four-year study period,32 and in Johannesburg, 
only 26% of patients with CD4 ≥350 cells/µl returned for a pre-ART wellness visit within one 
year.34  
Once a patient has been identified as eligible for initiating ART, it is essential that 
treatment is started promptly. However, only 39% of ART-eligible patients in a Durban 
cohort initiated treatment and another 20% died within 12 months of eligibility 
determination.35 A Cape Town-based study found that only two-thirds (67%) of eligible 
patients accessed ART within six months of testing,32 and a large study from the Free State 
found that 26% died prior to initiating ART.36  
A 2011 systematic review of patient attrition after HIV diagnosis and prior to ART 
initiation in sub-Saharan African cohorts found high overall attrition. The median proportion 
retained at each time period was 59% from HIV diagnosis to CD4 staging, 46% from pre-
ART care to ART eligibility (for those ineligible based on CD4 count), and 68% from eligibility 
to ART initiation. While none of the 28 studies reported cumulative retention through all of 
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the stages of pre-ART care, the product of the median proportions of patients retained at 
each time point suggested only 18% of patients were continuously retained in care through 
all three stages.37 
As the above summary describes, the recent awareness of the importance of pre-
ART retention has encouraged research quantifying patient attrition at specific time points in 
early HIV care – CD4 staging, pre-ART care for ART-ineligible patients, ART initiation – but 
very few studies have followed patient outcomes from the time of testing HIV-positive 
beyond ART initiation to report patient attrition. One previous study in rural Uganda from the 
early days of ART availability (2005-2007) reported retention from initial CD4 testing through 
ART initiation, but does not report on retention following ART initiation. The authors found 
rather high rates of return for early visits: 88% of patients eligible for ART returned for their 
CD4 staging visit, and 74% of eligible patients attended a third visit and started ART.38  
Another study from rural Malawi investigated attrition among patients with WHO stage 1 and 
2 disease through the first six months of HIV care (starting after CD4 testing), but without 
providing clear results for attrition by stage.39 They report that 89.7% of those who initiated 
ART were in care six months later, compared to 23.5% who did not initiate, but do not 
clearly differentiate attrition by ART eligibility status or account for the impact of differing visit 
schedules. The authors note that 95% of LTFU occurred between CD4 collection and results 
notification. This study also focused on a rural community, with markedly different facilities 
and services for patients on ART (dedicated clinics) and those not yet initiated (general 
outpatient services).  
A recent review of 28 pre-ART studies in sub-Saharan Africa concluded, “Offering a 
definitive answer to our core question—what proportion of patients who test positive for HIV 
are staged, enroll and remain in pre-ART care until ART eligibility, and initiate ART—is not 
possible…no study provides all the information needed to answer this question, even for a 
single setting.”37 To our knowledge, only one study from southern Africa has reported patient 
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retention at multiple time points from the time of testing HIV-positive beyond ART initiation. 
A study in Mozambique looked at five periods in early ART care: HIV testing, CD4 staging, 
enrollment at a separate ART facility, ART initiation and ART adherence at six months.25 
The study’s data were from the first year of the country’s ART program (2004-2005), when 
ART initiation sites were limited and separate from HIV testing sites. They found that among 
7,005 HIV-positive patients, 56.5% enrolled at the ART facility within 30 days of testing, 
77.1% of whom completed CD4 staging within 30 days of enrollment. Half (49.4%) of these 
patients were ART-eligible of whom 31.3% initiated ART within 90 days of CD4 testing. 
Using pharmacy data, the authors found that 83.0% of these patients were adherent to ART 
six months post-initiation. Attrition was highest between testing HIV positive and enrolling for 
ART care (43.5%) and between CD4 testing and ART initiation (within 90 days) for those 
ART-eligible (68.7%). However, this study does not report a cumulative measure of patient 
attrition from the time of testing HIV positive through ART retention, nor does it discuss 
attrition among patients ineligible for ART. 
In addition to incomplete and disjointed analyses of patient attrition, the definitions of 
patient attrition and LTFU vary widely among studies. As shown in the appendix, LTFU 
definitions vary, usually indicating an absence of from one to six months from a health 
facility, some requiring follow-up by clinic staff. Similarly, the time periods permissible for 
completion of key stages of early HIV care, such as CD4 staging and ART initiation differ 
significantly by study. The lack of a standardized definition for patient LTFU and time 
periods of care is a serious impediment to aggregating or generalizing results. In an attempt 
to overcome this heterogeneity of definitions, recommendations for standardized definitions 
for retention in pre-ART care have recently been proposed, allowing for estimates that can 
be compared across programs and countries.33  The recommendations are as follows: 
 Pre-ART stage 1: The proportion of patients who complete CD4 staging (including 
results notification) within three months of HIV testing. 
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 Pre-ART stage 2: For patients ineligible for ART, the proportion completing a repeat 
CD4 test within 12 months of first CD4 staging date. 
 Pre-ART stage 3: The proportion initiating ART within three months of determining 
ART eligibility. 
In addition to measuring the scope of the problem, investigations of patient attrition 
from early HIV care can identify groups who may be most at risk of dropping out of care. 
While the data above demonstrate that patient retention in HIV care is known to be an 
important challenge in the public sector throughout southern Africa, a few studies have 
suggested that pregnant women may have LTFU rates that exceed that of men and non-
pregnant women.40,41  A study from a community clinic in the North West Province of South 
Africa found that among 925 patients initiating ART, pregnant women had the highest 
cumulative probability of LTFU after six months, and pregnant women with a baseline CD4 
value ≤200 cells/µl were at six times the risk of LTFU than any other group (RR 6.06, 95%CI 
2.30, 16.71).41 Another study from outside Cape Town found higher LTFU in both the pre-
ART and post-ART periods among pregnant women, compared to non-pregnant women.40  
The largest study to date to explore LTFU among pregnant women, an analysis of nearly 
30,000 women initiating ART within five cohorts in South Africa, found that LTFU was 54% 
higher in pregnant women than in non-pregnant (aHR 1.54; 95%CI 1.38-1.72), despite less 
immunosuppression and decreased mortality.42 
 Another sub-population that may be at increased risk of LTFU is that of patients 
initiating ART at less advanced immunosuppression indicated by higher CD4 values. In late 
2009, the WHO revised their HIV treatment guidelines to expand eligibility criteria for ART to 
anyone with a CD4 count ≤350 cells/µl in order to treat patients before they develop 
advanced immunosuppression.43,44 Struggling to enroll and retain patients within their 
previous guidelines (eligibility at CD4 counts <200 cells/µl), South Africa revised its national 
ART guidelines in 2010 to expand eligibility to pregnant women and TB patients with CD4 
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counts ≤350 cells/µl, but did not immediately adopt WHO’s recommendations for early 
initiation for all.45 In August 2011, South Africa announced a revised policy of ART initiation 
for all adults with CD4 counts <350 cells/µl in response to recent developments in HIV 
research and international recommendations46 based on consensus that patients who 
initiate ART with a CD4 >200 cells/µl are at reduced risk of death and serious opportunistic 
infections, such as tuberculosis.47-50 There is already strong evidence that initiating at higher 
CD4 values also contributes to HIV prevention. The results of a large clinical trial 
demonstrated early treatment (CD4 counts 350-550 versus 250 cells/µl) reduced HIV 
transmission by 96%.51 Others advocate for a “test-and-treat” approach where all HIV-
positive patients start ART at the time of diagnosis regardless of CD4 count.52 
Given the recent policy change in South Africa, there are few studies that have 
explored LTFU among those initiating ART at CD4 counts 200-350 cells/µl versus <200 
cells/µl in southern Africa, and none in routine settings (see Table A.3). While initiating ART 
at higher CD4 values is known to be associated with improved clinical outcomes,48,50 it 
remains to be seen whether these gains will be overshadowed by increased LTFU. As part 
of a randomized controlled trial, a study in Johannesburg (N=812) found slightly higher 
LTFU among those initiating with a baseline CD4 >200 cells/µl (14%) than ≤200 (10%), 
suggesting that patients with higher CD4 counts may be more slightly likely to be lost from 
care.48 By comparison, Lesotho, a rural nation completely surrounded by South Africa, 
adopted an early initiation (<350 cells/µl) policy in 2007, and a study (N=1177) of patient 
outcomes under routine clinic settings showed that patients initiating ART with CD4 counts 
above 200 cells/µl were 39% less likely to be LTFU after nearly two years on treatment.47 
Given that South Africa’s national ART program recently raised its initiation threshold, it is 
essential that we evaluate the impact of early initiation on LTFU and other patient outcomes 
within a routine clinic setting.  
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To summarize, the body of research investigating patient attrition has increased 
substantially in the past decade, particularly in South Africa. However, notable areas for 
improvement and contribution remain. No study has followed a cohort from the time of HIV 
diagnosis through ART care to report on cumulative loss through consecutive stages of 
care. Additionally, no study has followed patients ineligible for ART long-term to understand 
retention in HIV care prior to ART initiation. Study generalizability is hampered by differing 
and often conflicting definitions of time periods of care and attrition and/or LTFU. Lastly, 
exploring the nuances of attrition among different sub-populations is an emerging topic, with 
early research suggesting that pregnant women have higher rates of LTFU than men or 
non-pregnant women after a period of follow-up, and no study reporting on the influence of 
higher CD4 values at ART initiation on LTFU within the setting of routine care in South 
Africa. In the context of this research environment, the present research study has been 
completed and three manuscripts describe the study findings.   
 
 
 
 
 
 
 
 
 
CHAPTER 2 
STATEMENT OF SPECIFIC AIMS 
Specific Aim 1: Compare retention among recently-diagnosed HIV-positive patients 
over multiple stages in the early HIV care process within a single clinic. 
 
In Chapter 4, Patient retention from HIV diagnosis through one year on antiretroviral 
therapy at a primary healthcare clinic in Johannesburg, South Africa, we compare the 
proportion of recently-diagnosed HIV-positive non-pregnant adult patients (N=842) retained 
in care through three stages of pre-ART and two stages of post-ART retention. We also 
report cumulative retention from the time of testing HIV-positive to 12 months on ART for 
those ART-eligible at testing, and from HIV testing to a repeat CD4 count for those ineligible 
for ART.  
Hypothesis 
Aim 1 is an descriptive analysis, so we are primarily concerned with investigating the 
proportions lost at each stage and cumulative retention. The research questions that 
motivate this aim are, “What is patient retention at each stage? At which stage is attrition 
highest?” We hypothesize that attrition will be highest prior to the initiation of ART. 
Rationale 
Patients who initiate ART have already successfully been retained for multiple visits 
and, thus, may be more inclined to continue in care. Studies that investigate patient 
retention starting at the time of ART initiation are missing pre-ART loss, which may be the 
period of highest attrition.  
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In Chapter 5 Loss to follow-up before and after delivery among women testing HIV-
positive during pregnancy in Johannesburg, South Africa, we investigate retention before 
and after delivery among women testing HIV-positive during pregnancy (N=273). 
Hypothesis 
Aim 1 is an descriptive analysis, so we are primarily concerned with investigating the 
proportions lost at each stage and cumulative retention. The research question that 
motivates this aim is, “Are pregnant women who test positive for HIV more likely to drop-out 
of care after delivery than before?” We hypothesize that patient loss will be higher after 
delivery than before delivery. 
Rationale 
In South Africa, most deliveries occur at hospitals, while antenatal and postnatal 
visits occur at the primary healthcare level. This disjointed system of healthcare is a barrier 
to continuous retention in care. In addition, travel around the time of birth may contribute to 
patient attrition in the postpartum period.  
 
Specific Aim 2: Measure the impact of initiating patients who present with CD4 counts 
200-350 cells/µl on patient loss to follow-up in a routine clinic setting.  
 
In Chapter 6, Initiating ART when presenting with higher CD4 counts results in 
reduced loss to follow-up under South Africa’s 2010 revised antiretroviral therapy guidelines, 
we evaluate the 12-month hazard of LTFU among patients initiating ART (N=1430) by 
baseline CD4 count to explore if LTFU is greater among patients with higher CD4 counts 
(200-350 cells/µl) than patients presenting with more advanced immunosuppression (CD4 
<200 cells/µl). 
Hypothesis 
We hypothesize that patients initiating ART with higher CD4 counts may be more 
likely to be LTFU. 
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Rationale 
Patients with less immunosuppression often feel healthier than patients who are 
sicker. Thus, the imperative of remaining in HIV care may be less obvious.  
 
 
 
 
 
 
 
 
 
CHAPTER 3 
RESEARCH METHODS 
Study setting and population 
 Witkoppen Health and Welfare Centre (Witkoppen) is a high-volume primary 
health clinic in Johannesburg, South Africa. Witkoppen sees about 8,500 patients a 
month, of whom about 40% are HIV-positive and a substantial proportion are recent 
immigrants from neighboring countries, predominately Zimbabwe. This high patient 
volume makes Witkoppen a well-suited setting for studies of HIV care and treatment. 
The clinic provides HIV/AIDS services (including the initiation and follow-up of ART), 
integrated HIV/TB services, family planning, pre-/post-natal care, pediatric services, 
chronic care, mental health services and social welfare assistance. Patient visits cost 
R40 (approximately US$5), but most patients’ visits are fully subsidized by the clinic due 
to patients’ inability to pay. Witkoppen is operated by a non-governmental organization 
and receives financial support from the Gauteng Department of Health, the President’s 
Emergency Plan for AIDS Relief (PEPFAR) through a South African NGO called Right to 
Care, and other public and private support. At Witkoppen, physicians and nurses with a 
primary healthcare nurse (PHCN) designation (similar in training and education to the 
nurse practitioner level in the US) may initiate patients onto ART as is called for under 
South Africa’s current ART recommendations. In general, patients at Witkoppen are 
treated according to the South African National Treatment Guidelines,45 with an 
important exception. In early 2010, Witkoppen began initiating all HIV-positive patients 
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with a CD4 count ≤350 cells/µl, over one year before South Africa adopted this policy 
nationwide.53 
 Witkoppen primarily serves a vast community of formal and informal settlements 
in Northern Johannesburg, such as Diepsloot, Cosmo City and Zandspruit, communities 
burdened with high unemployment, poverty and crime. The area is under-resourced in 
terms of public healthcare facilities and staff. Figure 2 shows Witkoppen as the red push-
pin; blue markers indicate all public clinics within the same municipal district (City of 
Johannesburg Region A), as well as two additional clinics (Zandspruit Clinic and 
Windsor Clinic) from areas in which Witkoppen patients reside. Of the clinics shown, 
Witkoppen is one of the largest, both in terms of patient loads and personnel.  
Figure 2. Map of Witkoppen Health and Welfare Centre and surrounding public clinics. 
 
Map courtesy of Google Maps 
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The setting of the proposed study provides a unique opportunity to examine LTFU at 
higher CD4 values under routine clinical care. Since Witkoppen is one of the few clinics in 
South Africa that has operated under a policy of initiation ≤350 cells/µl since 2010, we can 
examine the effects of implementing the WHO guidelines in a routine clinical setting using 
available data. LTFU here can be measured in the context of a highly integrated clinic: all 
relevant services – HIV counseling and testing, phlebotomy, ART initiation, antenatal care, 
as well as other clinic services – are available within the same facility, reducing the impact of 
having to access and wait at multiple facilities. Also, while slow time to initiation is often cited 
as a barrier to care and a factor contributing to LTFU, Witkoppen has a demonstrated ability 
to initiate patients onto ART promptly. Previous linkage to care studies in South Africa 
performed at government facilities found a median time from HIV diagnosis to ART initiation 
(among eligible patients) ranging from 95 days to 6.6 months.35,36 In contrast, a 2011 study 
of TB suspects at Witkoppen indicated that the median time from HIV diagnosis to ART 
initiation was 26.5 days with 70% of patients eligible for ART initiated.54 Before ART 
initiation, patients must receive necessary ART counseling, but appointments are scheduled 
with an understanding of the need for prompt initiation, particularly for patients presenting 
with advanced immunosuppression. This means that we can measure LTFU within the 
setting of a clinic that has already worked to reduce some of the known barriers to retention, 
including multiple facilities and deferred care. We would expect that other clinics that have 
not implemented such integration measures may experience higher patient attrition. 
 
Ethical considerations 
Ethical approval for this analysis was granted from the Public Health-Nursing IRB at 
the Office of Human Research Ethics at the University of North Carolina at Chapel Hill and 
the Human Research Ethics Committee of the University of the Witwatersrand. This analysis 
17 
 
was conducted using routine data collected in patient files as standard clinical procedure 
and did not require individual patient consent.  
 
Data collection 
 For Aim 1, we conducted a retrospective observational cohort (N=1144) study 
through patient files review. To determine patient outcomes, records were reviewed a 
minimum of 12 months (median 16.5 months, IQR: 14.8-18.1) from the time of testing 
HIV-positive. For patients whose CD4 count at the time of HIV testing made them 
eligible for ART who went on to begin ART, files were reviewed a minimum of one year 
post-ART initiation. Data were single-entered into a Microsoft Excel 2010 (Microsoft 
Corp., Redmond, WA) spreadsheet by KC and analyzed using SAS, version 9.2 (SAS 
Institute, Cary, NC). The files of 18 patients (1.6%) could not be retrieved after multiple 
attempts, so data were obtained from the clinic’s electronic medical records system. Of 
these patients, six were pregnant and contributed to Chapter 5. Because the policy of 
using a higher ART initiation threshold was new at Witkoppen in 2010, individual 
eligibility for ART was assessed for each patient during the file review, which led clinician 
decision to deem 23 patients with CD4 values 200-350 being ineligible for ART and 
three patients with CD4 >350 cells/µl eligible. 
For Aim 2, we also used a retrospective cohort (N=1430), but used data 
electronically captured at Witkoppen using TherapyEdge-HIV™ Patient Management 
System (Associated Biological Systems, South Africa). Data are captured at the clinic by 
data capturers and clinicians, and are regularly quality-checked by a data manager. Data 
were exported from TherapyEdge-HIV™ and analyzed using SAS, version 9.2. 
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Eligibility and exclusion criteria 
For Aim 1, our inclusion criteria were adult patients (18 years and older) who tested 
HIV-positive for the first time at Witkoppen from 1 January – 30 June 2010. We started with 
a roster from the clinic data manager of all 1612 patients who likely met the inclusion criteria, 
listing only clinic file number and date of testing. Of these, 23 (1.4%) patients less than 18 
years old and 320 (19.9%) patients who tested HIV-positive elsewhere and already knew 
their HIV status were removed for failure to meet inclusion criteria. This left 1270 patients on 
the roster, from which we excluded the following groups: 
 Invalid clinic file numbers (seven digits instead of six) (n=3, 0.2%) 
 Patients who could not be identified using the file number provided: a paper file 
could not be located after at least three separate attempts and the file number was 
not found in TherapyEdge-HIV™ (n=122, 9.6%). While it is possible for paper files to 
go missing, it is unlikely for a patient who tests HIV-positive to be missing a paper 
file and also not be found in TherapyEdge-HIV™. For this reason, we believe that 
the file numbers provided to us by the data manager for these 122 patients were 
erroneous.  
This left 1144 individuals for analysis for Aim 1. Of these, 844 were not pregnant and were 
analyzed in Chapter 4. The remaining 300 were pregnant at the time of testing HIV-positive 
and were analyzed in Chapter 5. 
 For Aim 2, our inclusion criteria were adult patients who initiated ART for the first 
time at Witkoppen between April and December 2010. We exported TherapyEdge-HIV™ 
data on 1699 patients from Witkoppen’s server on May 6, 2012 who were likely eligible. 
After removing 67 (3.9%) patients less than 18 years old and 118 (6.9%) patients who were 
not ART-naïve, we were left with 1514 patients. From this total, we excluded the following: 
 Patients missing a baseline CD4 value (n=29, 1.9%) 
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 Patients with a baseline CD4 value >350 cells/µl (n=55, 3.6%) 
This left 1430 individuals in our analysis dataset for Aim 2. 
 
Pre- and post-initiation clinic visit schedule 
Patients with CD4 values ≤350 cells/µl or those with WHO clinical stage 3 or 4 
disease are eligible to start ART at Witkoppen. For ART-eligible patients, South African 
treatment guidelines stipulate initiation of ART at the third patient visit, following clinical 
assessments and adherence counseling. However, patients with CD4 counts <100 cells/µl, 
those with MDR/XDR-TB, stage IV disease, or pregnant patients eligible for ART are 
designated to be fast-tracked to begin ART within two weeks of diagnosis. Patients ineligible 
for ART are to be enrolled in a “wellness program,” which are poorly defined in national 
guidelines, apart from providing routine HIV care with CD4 monitoring every six months. At 
Witkoppen, wellness services also include TB screening at every visit, ongoing HIV 
counseling, family planning and Pap smears.45 
While actual visit schedules vary based on patient and clinic availability, the general 
schedule of visits at Witkoppen is as follows.  
Visit 1: Diagnosis visit. HIV testing begins with pre-test counseling, typically administered in 
small groups. Patients then go individually to a separate room for HIV testing via finger 
pricking. Witkoppen utilizes two simultaneous dried blood spot rapid tests (First Response, 
Premier Medical Corp., Ltd., Kachigam, India), packaged individually, with HIV testing 
results available within 5-20 minutes. All patients receive immediate individual post-test 
counseling. If the patient tests positive, after examination by a nurse, he or she is sent for 
blood collection for CD4 count testing, still on the same date as diagnosis. Patients are 
given a scheduled date to return for CD4 results, usually one to four weeks after Visit 1. 
Visit 2 (1-4 weeks after Visit 1): CD4 staging visit. At the second visit, the patient receives 
his or her CD4 count results, followed by a full clinical assessment by a physician. At 
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Witkoppen, counselors provide CD4 results, along with a through explanation of the 
meaning of the result. If the patient is eligible to initiate ART, a first adherence counseling 
session is provided concurrently. Counseling messages regarding adherence are not known 
to have been revised or improved during the study period. If the patient is not eligible for 
ART, he or she will be scheduled to return six months later for repeat CD4 testing and 
clinical follow-up. 
Visit 3 (1-4 weeks after Visit 2): ART initiation visit. If the patient is eligible to initiate ART, a 
second adherence counseling session is commenced at this visit. Following successful 
completion of two adherence sessions, the clinician initiates ART. If the patient has been 
designated for fast-track initiation based on CD4 value, the first three visits are 
recommended to occur within two weeks. 
Visit 4 (1 month after Visit 3): First post-ART visit. Following ART initiation, the first post-
initiation follow-up clinical visit is scheduled for approximately one month after initiation.  
Visits 5+. Subsequent medical visits and counseling are scheduled for one- or two-month 
intervals, depending on the patient’s clinical condition. Typically, patients on ART return on a 
monthly basis until they are considered stable and adherent (usually 5-6 months after 
initiation), at which time they may be given multi-month ART prescriptions, or may be 
transferred out to other clinics for care. For patients who remain at the clinic, CD4 and viral 
load testing is repeated six and 12 months after initiation and annually thereafter. 
Antenatal visits: For pregnant women, South Africa’s maternal health guidelines recommend 
antenatal clinic (ANC) visits start as early as possible in pregnancy, and the basic antenatal 
schedule for women includes five visits prior to delivery, regardless of HIV status, scheduled 
at 14, 20, 26, 32 and 38 weeks gestation.55 The national guidelines stipulate a maternal 
prevention of mother to child transmission (PMTCT) regimen for all HIV-infected women with 
twice-daily zidovudine (AZT) beginning at 14 weeks gestation; intrapartum single-dose 
nevirapine and three-hourly AZT; and postpartum single-dose tenofovir and emtracitabine.56 
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Additionally, for pregnant women with a CD4 value ≤350 cells/µl, lifelong ART should be 
initiated as soon as possible.45 For HIV-positive women, there are no guidelines for 
combining ANC and HIV visits, so clinics are expected to dovetail HIV activities (CD4 results 
notification, ART initiation, etc.) with ANC visits.  
 
Statistical analysis 
Outcome: Chapter 4 
The primary outcome for the first manuscript is the proportion of adult, non-pregnant, 
recently-diagnosed HIV-positive patients retained in care at Witkoppen during each of the 
following stages of early HIV care: 
 Pre-ART stage 1: HIV diagnosis to CD4 results notification 
 Pre-ART stage 2: For those not eligible for ART at staging (CD4 >350 cells/µl) from 
CD4 results notification to eligible for ART 
 Pre-ART stage 3: ART eligibility at staging to ART initiation 
 Post-ART 0-6 months: ART initiation to six months after ART initiation 
 Post-ART 6-12 months: Six months to 12 months after ART initiation 
 
Completing each stage is defined as the proportion of patients who achieve each of 
the following milestones of early HIV care within each time period described above: 
 Pre-ART stage 1: CD4 staging (including results notification) completed within three 
months of HIV diagnosis 
 Pre-ART stage 2: For patients ineligible for ART, repeat CD4 test completed within 
12 months of first CD4 staging date 
 Pre-ART stage 3: ART initiated within three months of ART eligibility determination 
 Post-ART 0-6 months: Retained in care for up to six months after ART initiation  
 Post-ART 6-12 months: Retained in care for up to 12 months following six months on 
ART 
 
We define patient retention as being alive and in care and not transferred and patient 
attrition as either patient drop-out or death. For participants for whom South African ID 
numbers are available, mortality outcomes were identified and confirmed by using the 
National Population Registry (death registry) of the South African Department of Home 
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Affairs in October 2011, at the end of follow-up.22 Patients who requested a transfer to 
another clinic are noted and removed from the analysis at the start of the stage in which 
they transferred. 
Cumulative retention among ART-eligible patients is defined as completing pre-ART 
stages 1 and 3, and remaining on ART for at least 12 months. For those who were ART-
ineligible at the time of testing HIV-positive, cumulative retention is defined as completing 
pre-ART stages 1 and 2.  
Exposure: Chapter 4 
As aim 1 is a descriptive analysis, we are primarily concerned with investigating the 
proportion retained at each stage. However, we also investigate the effect of baseline 
characteristics as independent predictors of attrition in the any pre-ART and post-ART (0-12 
months) time period.  
Covariates: Chapter 4 
We explore the following patient characteristics as independent predictors of attrition 
at any pre-ART stage and post-ART (0-12 months): sex, age, CD4 count at the time of HIV 
testing, nationality, employment status, HIV positive at first visit to the clinic, and TB 
treatment at time of HIV diagnosis. 
Analytic methods: Chapter 4 
 Baseline patient characteristics are summarized using counts and proportions for 
categorical variables and interquartile ranges (IQRs) for continuous variables. We report 
retention at the three stages of pre-ART care and two post-ART time points as counts and 
proportions with 95% confidence intervals (95%CI). Cumulative retention is reported using 
proportions and 95%CI and excludes patients who transfer at any point during the analysis. 
We identified predictors of any pre-ART or post-ART attrition by estimating adjusted risk 
ratios and 95%CI obtained by log-binomial regression analysis.  
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Outcome: Chapter 5 
The primary outcome for the second manuscript is the proportion of recently-
diagnosed HIV-positive pregnant patients retained in care at Witkoppen during the antenatal 
and postnatal periods. These periods are described in greater detail in the “analytic 
methods” section below.  
Exposure: Chapter 5 
As above, Aim 1 is a descriptive analysis, so we are primarily concerned with 
measuring the proportions lost at each stage. However, we also investigate the effect of 
baseline characteristics as independent predictors of LTFU before and after delivery. 
Covariates: Chapter 5 
We explore the following patient characteristics as independent predictors of attrition 
before and after delivery: age, CD4 count at the time of HIV testing, nationality and timing of 
first ANC visit. 
Analytic methods: Chapter 5 
Patient characteristics are described using proportions and 95%CI for categorical 
variables, and medians and IQR for continuous variables. We examine retention among 
pregnant women in two ways. Firstly, we report retention through several stages of pre- and 
post-ART care within the antenatal and postnatal periods using counts and proportions with 
95%CI. The activities of early HIV in the stages used in Chapter 5 are similar to those in 
Chapter 4 (i.e., CD4 staging, ART initiation, etc.) but the timing of the events relates to 
before and after delivery. The first stage for all patients is completing CD4 staging, including 
results notification, prior to delivery. For those ART-eligible, subsequent stages include ART 
initiation prior to or after delivery, completing a clinic visit after delivery, and six months 
retention on ART. ART initiation prior to delivery is a key component of South Africa’s 
PMTCT program56 and maximal effectiveness of ART for PMTCT has been shown to be 
reached around 13-15 weeks prior to birth.57,58 For ART-ineligible patients, subsequent 
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stages are returning for a clinic visit after delivery and receiving a repeat CD4 test after 
delivery. A diagram of these stages is presented in Figure 6 in Chapter 5. Retention is 
defined as completing each stage and is determined using clinic visit data. Patients who 
transfer are noted and removed from the analysis at the start of the stage in which they 
transferred.  
Cumulative retention among ART-eligible women is defined as receiving CD4 results 
and initiating ART before delivery and remaining on ART for at least six months. Among 
those ART-ineligible, cumulative retention is defined as receiving CD4 results before 
delivery and returning for a repeat CD4 test after delivery. Cumulative retention analyses 
exclude patients who transferred during the antenatal (n=6) and postnatal (n=11) periods.  
Secondly, we use time-to-event analysis to assess LTFU before and after delivery by 
estimating person-time in the antenatal and postnatal periods. LTFU, the outcome for this 
part of the analysis, is defined as not returning to the clinic within one month after the last 
scheduled visit. A one-month definition of LTFU is shorter than used in many studies, but 
pregnant women in antenatal care have more repeat visits within a short time period leading 
up to birth, thus one month after the last scheduled visit indicates that the patient is likely 
well off the clinic schedule. The one-month definition also allowed us to determined loss to 
follow-up in the antenatal period despite late presentation for the first ANC visit. For the 
antenatal period, person-time began accruing at testing HIV-positive and ended at the first 
of the following three events: 1) delivery, 2) loss to follow-up or 3) transfer to another facility 
prior to delivery. For women remaining in care during the postnatal period, person-time 
began accruing at delivery and ended at the first of 1) six months after delivery, 2) loss to 
follow-up or 3) transfer after delivery. No deaths were reported during the antenatal and 
postnatal time periods studied, so these represent all possible outcomes. After confirming 
the assumption of proportional hazards using the martingale residuals method (ASSESS 
statement in SAS), we examined predictors of overall loss within the antenatal and postnatal 
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periods using Cox proportional hazard regression and report adjusted hazard ratios and 
95%CI. In the visual display of these results (Table 5), we also include LTFU rates 
(proportion LTFU/person-time) for each category presented.  
Outcome: Chapter 6 
 In Chapter 6, the primary outcome is LTFU, defined as not returning to the clinic 
within three months after the last scheduled visit. Secondary outcomes are mortality, which 
is obtained from the clinic file and from data linkage with the National Population Registry 
(South African Department of Home Affairs) and incident tuberculosis, defined using ICD-10 
codes for any diagnosis of pulmonary M. tuberculosis infection after ART initiation date.   
Exposure: Chapter 6  
As shown in pink in Figure 3, baseline CD4 value at the time of initiating ART is the 
primary exposure in Chapter 6. Baseline CD4 is defined as the CD4 value closest to ART 
initiation, during a window six months prior to ART initiation to seven days post-initiation, 
and is categorized into ≤200 cells/µl and 201-350 cells/µl. 
Figure 3. Directed acyclic graph (DAG) for potential confounders of the association 
between baseline CD4 value and loss to follow-up. 
 
Covariates: Chapter 6 
 Covariates considered in Chapter 6 are shown in white in Figure 3 and are described 
in detail below. 
Gender Pregnancy Age
Access to care (U) Baseline CD4 LTFU
Employment TB co-infection Nationality Marital status, distance to clinic, SES, 
education, history of care
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 Age is categorized 18-29, 30-39, ≥40 years and will be examined as a potential 
confounder. Two dummy variables were created for age 18-29 and ≥40 years, with 30-
39 years as the referent group. Age may affect CD4 and LTFU if health-seeking 
behaviors differ by age. We hypothesize that patients in the younger age groups are 
more likely to be LTFU. 
 Pregnant at ART initiation and gender. Prevalent pregnancy was first explored as a 
potential effect measure modifier. Pregnant HIV-positive women at Witkoppen often 
have higher baseline CD4 values than the general clinic population due to routine ANC 
testing. In terms of LTFU, pregnant women receive more frequent care from different 
clinicians at a separate clinic within Witkoppen and also may be traced more 
aggressively by the clinic upon missing a visit. We assessed for relative effect measure 
modification by including an interaction (pregnancy*CD4) variable in the model, and 
found that when including the interaction term our estimate of CD4 on LTFU was 
substantially affected.  Thus, we concluded that the estimate of baseline CD4 on LTFU 
was modified by pregnancy and we present results stratified by a three-level gender 
variable (non-pregnant female, male, pregnant female) at each of the two CD4 
categories. This allows us to compare the effect of presenting for care and initiating at 
higher and lower CD4 groups by both gender and pregnancy status. Prior research 
suggests that pregnant women have equal or higher rates of LTFU than other 
adults;40,59,60 thus we hypothesize that they may be more likely to be LTFU. 
 Nationality is a binary variable representing South Africa-born or foreign-born and was 
examined as a potential confounder. Witkoppen serves many recent immigrants to 
South Africa, and migration may influence retention in care. CD4 count also may be 
affected if nationality or migration affects access to care. Country of birth is used as a 
proxy for migration. Most foreign-born patients at Witkoppen are from Zimbabwe, with 
small numbers of patients from other neighboring countries, so we will group all foreign-
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born patients into one category. We hypothesize that patients born outside of South 
Africa are more likely to be LTFU due to instability and frequent migration. 
 Employment status may influence a patient’s ability to access to care, thus CD4 values 
and LTFU. Witkoppen offers free services to patients who cannot pay, but transport 
costs to the clinic are frequently reported by patients as a financial barrier. Alternatively, 
patients with regular employment may be unable to take time off work to attend clinic 
visits. We will investigate employment status as a potential confounder and hypothesize 
that employed patients are less likely to be LTFU. We do not have data on type of work, 
so we cannot investigate the effect of different types of jobs or potential heterogeneity 
among the employed by type of work. 
 Prevalent TB at ART initiation is coded as a binary variable and was investigated as a 
potential confounder. Prevalent TB is defined as any diagnosis of pulmonary M. 
tuberculosis infection with a TherapyEdge-HIV™ start date prior to ART initiation and 
end date after initiation. TB start date is defined in TherapyEdge-HIV™ as diagnosis 
start date and end date is defined as the date treatment ends. Patients with TB may be 
sicker than patients without TB, since TB is an opportunistic infection that affects those 
with advanced immunosuppression, and TB itself lowers CD4 count. Also, those on TB 
treatment may see a CD4 increase even prior to initiating ART. Since TB affects both 
CD4 count and LTFU, we will investigate it as a potential confounder and hypothesize 
that patients co-infected with TB may be more likely to be LTFU.  
Covariates that may affect the association between baseline CD4 value and LTFU, 
but not included in the analysis, are shown in yellow in Figure 3. We did not include marital 
status because this is not captured in TherapyEdge-HIV™. Also, the high prevalence of 
common law/traditional marriages, as well as polygamous marriages in South Africa makes 
the variable difficult to interpret. We also did not evaluate distance to Witkoppen because 
the clinic almost exclusively serves a specific nearby geographic region, including the areas 
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of Diepsloot and Cosmo City, which is 10-15 minutes from the clinic by public transport. 
Socio-economic status (SES) markers, such as household income or inventory, are not 
available in TherapyEdge-HIV™. As mentioned earlier, Diepsloot is a very poor informal 
settlement. Education is poorly captured in TherapyEdge-HIV™ and history of care is not 
available. A previous study at Witkoppen found that 29% of patients suspected of TB did not 
attend high school.54   
Analytic methods: Chapter 6 
Continuous variables are described using medians and IQR; categorical variables by 
counts and proportions. For patients who did not die within 12 months of ART initiation, 
person-time for the LTFU analysis began accumulating at ART initiation ended at the 
earliest of: 1) 12 months of follow-up, 2) loss to follow-up or 3) transfer. Patients who died 
within 12-months of ART initiation were followed from ART initiation to their date of death, 
even if previously considered lost. For the outcome of incident TB, person-time ended at the 
first diagnosis of TB within 12 months ART initiation or at death, or if neither of those 
outcomes, at the earliest of 1, 2 or 3 above.  
After confirming the assumption of proportional hazards using the martingale 
residuals method (ASSESS statement in SAS), we used Cox proportional hazard methods 
to estimate 12-month loss to follow-up, mortality and incident TB, as well as predictors of 
these outcomes, and reported these using adjusted hazard ratios and 95%CI. Covariates 
were included in the model as confounders if they resulted in a meaningful change in 
estimate (≥10%) and/or based on prior knowledge and direct acyclic modeling. We produced 
crude Kaplan-Meier curves depicting time to loss, mortality and incident TB by CD4 group 
and compared them using the log-rank test for equality of survivor functions using Stata 12 
(StataCorp LP, College Station, TX). To assess for misclassification of death as LTFU 
among patients without a South African national ID, we conducted a sensitivity analysis 
restricted only to patients with a valid South African ID number. This sensitivity analysis did 
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not change the size of our effect or our conclusions. We also accounted for death as a 
competing risk on our estimate of loss to follow-up by utilizing the Fine and Grey model for 
competing risks analysis in Stata 12 and reported the subdistribution hazard ratio and 
95%CI. This analysis considers our event of interest (LTFU) in the presence of other events 
(death) that may preclude the primary event from occurring. That is, under standard 
methods, if a patient dies before meeting our definition of LTFU, then the patient is censored 
and can no longer develop the outcome of interest. Competing risks analyses are 
recommended to correct for potential overestimation of the proportion obtaining the event of 
interest when calculating cause-specific hazard ratios.36,61,62 
 It is important to note that the available data do not allow us to answer the ideal 
research question, which is, “What is the effect on loss to follow-up among patients with a 
CD4 count between 200-350 of initiating ART immediately (at a CD4 count between 200-
350) versus deferring treatment until the CD4 count falls below 200?”  In order to answer 
that question, we would need pre-ART data to measure LTFU and deaths prior to ART 
initiation for those in the deferred arm, but pre-ART data are incomplete and unreliable on 
TherapyEdge-HIV™. If such data were available, we could use marginal structural modeling 
techniques, which would allow for time-dependent confounding affected by prior 
exposure.63,64 Given the limitations of our data, the appropriate question to ask is, “Among 
those who are eligible for ART at the time of testing, what is the effect of baseline CD4 at 
the time of ART initiation on LTFU?”  In this scenario, there is no time-varying confounding 
because our exposure (baseline CD4) is at one time point only (ART initiation). We are 
estimating LTFU among patients who survived until ART initiation and as such our results 
cannot be interpreted as a causal relationship. 
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Study limitations 
The primary limitation of this study is that we cannot know if patients continue care at 
another facility, except among those patients who request an official transfer. This is a 
limitation that is shared by many studies investigating LTFU due to unlinked patient records. 
Transfers are classified as a separate outcome from LTFU, but it is possible that patients 
seek care elsewhere without requesting a formal transfer. It is also possible that patients 
test for HIV at Witkoppen but seek a second opinion at a different facility, and continue care 
there. In this study, LTFU must be understood to mean lost from Witkoppen only. The study 
setting, Witkoppen, is only one clinic, and one that is particularly well-integrated and 
comparatively well resourced. Thus, the results may not be generalizable to other clinics 
throughout South Africa with more limited resources and less integration, where LTFU may 
be greater than what we found at Witkoppen.  
 These study data are limited, as other retrospective studies, to those which are 
routinely collected in the patient file or in TherapyEdge-HIV™. File reviews may be 
inexact and incomplete if certain information is not recorded by the clinician at the time 
of the visit. Data on TherapyEdge-HIV™ are more likely to be missing than those from 
the file review, and data most likely to be missing include co-infection diagnosis (such as 
TB) and visit dates, particularly for patients prior to ART initiation. Since TherapyEdge-
HIV™ data is especially poor for pre-ART patients, pre-ART data is only obtained via the 
file review. Unlike prospective studies, we are limited to the information at hand and 
cannot request specific information from clinicians about each patient from past visits. 
Furthermore, we cannot know the reason why LTFU patients might have dropped out of 
care with the information provided in the files. However, reviewing patient files 
retrospectively allows us to evaluate patient retention under real-world conditions and 
following the clinic’s protocol, not a specific research protocol which might limit 
generalizability if visit scheduling and patient follow-up differed from standard practice. 
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Another limitation is the short follow-up period. Given that Witkoppen began its early 
initiation policy in early 2010, we only have data through one year after ART initiation. If we 
extended the study period, we could examine post-initiation retention, as well as pre-ART 
retention for those ART-ineligible, for a longer period. However, previous studies have 
shown that the first year of care is a period of high rates of pre-ART and post-initiation 
LTFU, so this study period provides the opportunity to look closely at the time periods when 
patients are lost within the first year of care and when interventions to address patient loss 
might be most useful. Some of the patients categorized as LTFU could turn out to be 
temporary care interruptions if they eventually return to care. Temporary interruptions and 
missed visits will not be addressed by this study. Given a longer study period, we could 
possibly see an increase in patients once considered LTFU returning to care. 
 Lastly, Witkoppen cares for a large proportion of patients from outside of South 
Africa, but deaths can only be confirmed using the South African national death registry 
using a valid South African ID number. This limits our ability to confirm death and raises the 
possibility that some patients classified as LTFU may in fact have died, which would 
overestimate our LTFU result and underestimate our mortality result. 
 
 
 
 
 
 
 
CHAPTER 4 
PATIENT RETENTION FROM HIV DIAGNOSIS THROUGH ONE YEAR ON 
ANTIRETROVIRAL THERAPY AT A PRIMARY HEALTHCARE CLINIC IN 
JOHANNESBURG, SOUTH AFRICA 
 
Introduction 
South Africa’s national antiretroviral therapy (ART) program is currently the largest in 
the world, with over 1.7 million adults and children enrolled in the first seven years.1,4 Rapid 
scale-up has put tremendous pressure on the limited resources of the public health sector. 
Despite the fact that 300,000 patients enroll in the South African ART program each year,5 
an estimated 250,000 people died of AIDS in 20103 and only 52% of those currently ART-
eligible are receiving treatment.4 
An enormous challenge to South Africa’s attempts to expand the impact of its 
program is attrition from HIV care. Uninterrupted retention for HIV patients is critical as 
patients who stop treatment are at increased risk of drug resistance, morbidity and 
mortality.20,21 Several studies have documented rates of retention on ART in resource-limited 
settings,15,26,27,60,65 and have demonstrated that during the first year on HIV treatment 
patients are at high risk for attrition (i.e., programmatic loss and mortality).27-29 More recent 
work has documented high rates of attrition among patients not yet on ART from the time of 
testing positive to completion of CD4 staging,30,31 from completing staging to repeat CD4 
testing for ART eligibility,32,34 and from ART eligibility to ART initiation.32,35,36  
While these studies highlight a problem with attrition from HIV care, three major 
limitations impede conclusions about the extent of the problem. First, progression through 
the consecutive stages of HIV care (e.g., testing positive, CD4 staging, ART initiation) are 
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typically studied in isolation among distinct cohorts which prevents a measure of overall 
program attrition from the time of testing positive through long-term ART. To our knowledge, 
only one study has examined retention through pre-ART and post-ART stages among 
patients in Southern Africa. Using data from the first year of  the public ART program (2004-
2005) in Mozambique, Micek et al. reported data from separate HIV testing and treatment 
facilities and found retention was lowest at the period of enrollment at the ART sites (56.5%) 
and for timely ART initiation among ART-eligible (31.3%), but did not report cumulative 
retention through all stages or describe retention among patients ineligible for ART.25 
Second, operational definitions of patient retention differ greatly between studies, limiting 
comparability. Recommendations for standardized definitions for pre-ART care have 
recently been proposed,33 allowing for estimates that can be compared across programs 
and countries. Third, most national HIV programs do not report retention indicators during 
pre-ART care, so we currently have no way of quantifying the magnitude of loss to initiation 
at the country level. 
To address the limited longitudinal measures of attrition from HIV care across 
multiple stages of care, we set out to measure attrition through five stages of early HIV care 
at a single site in a cohort of patients testing positive using the newly recommended 
definitions. 
 
Methods 
Study setting 
Witkoppen Health and Welfare Centre (“Witkoppen”) is a high-volume (8,500 patient 
visits per month) primary healthcare clinic in Johannesburg, South Africa, operated by a 
non-governmental organization receiving public and private financial support. Witkoppen 
provides HIV/AIDS services, integrated TB/HIV care, pre/post-natal care, chronic care, 
mental health services and social welfare assistance to a primarily low-income population 
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residing in densely-populated peri-urban formal and informal settlements in northern 
Johannesburg.  
 
Pre-ART care at Witkoppen begins at the time of testing HIV-positive using two 
simultaneous rapid dried blood spot tests, with results available in about 20 minutes. Blood 
for CD4 testing is drawn at the clinic on the same day a patient receives a positive HIV result 
and is sent to an off-site National Health Laboratory Services (NHLS) facility. Patients are 
scheduled to return for CD4 results 2-4 weeks after testing positive. At this second visit, 
ART-eligible patients attend a first adherence counseling session and are examined by a 
clinician. Blood is collected for additional baseline tests, and they are scheduled to return 2-
4 weeks later for a second adherence counseling session and ART initiation. Patients 
initially ineligible for ART receive counseling about their CD4 result, are examined by a 
clinician, and are scheduled to return for a follow-up CD4 test within six months. Patients – 
both pre-ART and on-ART – who miss scheduled appointments are to be phoned by clinic 
staff for rebooking, and if untraceable, to be referred for community outreach tracing. 
ART is initiated on-site by doctors and qualified nurses. Patients at Witkoppen are 
generally treated according to the South African National Treatment Guidelines,45 with an 
important exception. In 2010, Witkoppen began initiating all HIV-positive patients with a CD4 
count ≤350 cells/µl, a year before South Africa adopted this policy nationwide.53  
 
Study design 
We conducted an observational cohort study through retrospective clinical record 
review of all non-pregnant adult individuals at Witkoppen testing HIV-positive for the first 
time between 01 January–30 June 2010 (N=969). Starting with a roster of eligible patients 
sourced from the clinic’s monthly HIV testing statistics, we excluded patients whose paper 
files could not be located after three separate attempts using the clinic number provided and 
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were unlisted in TherapyEdge-HIV™, the electronic clinic HIV patient database (N=125), 
suggesting an invalid clinic ID number or erroneous inclusion on the list of eligible patients. 
We also excluded two patients who transferred facilities immediately after testing HIV-
positive. For the 842 patients included in the analysis, we reviewed clinic files after a 
minimum of 12 months (median 16.5 months, IQR 14.8-18.1) from the time of testing HIV-
positive or at least 12 months post-initiation for those who were initially eligible for ART. 
Data were collected using Microsoft Excel 2010 (Microsoft Corp., Redmond, WA). 
 
Approval for this study was granted by the Human Research Ethics Committee of the 
University of the Witwatersrand and the Institutional Review Board of the University of 
North Carolina at Chapel Hill.  
 
Definition of study variables 
Retention was defined as remaining alive and in care at Witkoppen and was 
determined using clinic visit dates. Attrition refers to both loss to follow-up (no clinic 
attendance ≥3 months after last scheduled visit) and death but does not include transfers. 
Patients who transfer are removed from the analysis at the start of the stage in which they 
transferred. Missed visits among patients who returned to care and treatment interruptions 
do not contribute to our definition of retention. We defined three stages of pre-ART care37 
using standardized definitions33 for retention in each stage as defined in Table 1. For pre-
ART stage 1, we report the proportion of patients who complete CD4 staging within three 
months after testing HIV-positive. For pre-ART stage 2, we report the proportion of patients 
not eligible for ART who received a second CD4 test within one year after the first CD4 
staging. Patients eligible for ART at the time of HIV diagnosis skip pre-ART stage 2 and 
move directly to pre-ART stage 3, where we report the proportion of patients initiating ART 
within three months after being determined ART-eligible. Eight patients (0.9%) reported 
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initiating ART at other facilities without transferring out and returned to Witkoppen, so the 
date initiated elsewhere was used. We report post-ART retention at six and 12 months after 
ART initiation. Retention within a stage is dependent on successfully completing the prior 
stage. Cumulative retention analyses exclude patients who transferred during the stages 
reported (n=59). 
Table 1. Definitions of stages of early HIV care. 
 
Pre-ART stage definitions per Fox, Larson, Rosen, 2011.
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We defined initial CD4 count as the value at the time of testing HIV-positive. ART-
eligibility at the time of testing HIV-positive was confirmed during the file review and is 
generally defined as a CD4 count ≤350 cells/µl; however, 23 patients with CD4 values 200-
350 cells/µl were considered ineligible for ART due to clinician non-compliance with the 
clinic’s ART guidelines and three patients with CD4>350 cells/µl were considered eligible at 
clinician discretion. TB treatment was defined as initiating TB treatment within one year of 
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testing HIV-positive. For patients with an available South African ID number (33.9% of 
patients lost to follow-up) mortality was confirmed using the National Population Register of 
the South African Department of Home Affairs.22  
 
Statistical analysis 
Patient characteristics at the time of testing HIV-positive were summarized using 
counts and proportions for categorical variables and medians and interquartile ranges 
(IQRs) for continuous variables. We report retention at the three stages of pre-ART care and 
two ART time points as counts and proportions with 95% confidence intervals (95%CI). We 
identified predictors of any pre-ART or post-ART attrition by estimating adjusted risk ratios 
(aRR) and 95%CI obtained by log-binomial regression analysis. 
 
Results 
Characteristics of the 842 eligible patients are summarized in Table 2. Overall, 
55.1% were female. Patients were a median (IQR) of 34 years (28-40) and had a median 
(IQR) initial CD4 count of 212 (92-350) cells/µl. Nearly half (41.5%) were born outside South 
Africa, mostly in Zimbabwe (75.9% of foreign-born), and 72.6% tested HIV-positive on their 
first visit to Witkoppen. Initial CD4 values were not available for 32 patients (3.8%) due to 
the patient leaving prior to CD4 testing (n=25) or missing lab results (n=7) and never 
returning for repeat testing. Of the remainder, 589 (72.7%) were ART-eligible when testing 
HIV-positive. Nearly 11% of patients initiated TB treatment within a year of HIV testing.  
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Table 2. Characteristics of the study participants (N=842). 
Sex, n (%)     
   Female   464 (55.1) 
   Male   378 (44.9) 
      
Age at HIV testing, median (IQR)   34 (28-40) 
Age at HIV testing, n (%)     
  18-29 years   254 (30.2) 
  30-39 years   352 (41.8) 
  40 years and older   236 (28.0) 
      
First CD4 value (cells/µl), median (IQR)   212 (92-350) 
First CD4 value, n (%)     
  <50 cells/µl   102 (12.1) 
  50-199 cells/µl   282 (33.5) 
  200-350 cells/µl   225 (26.7) 
  >350 cells/µl   201 (23.9) 
  Missing   32 (3.8) 
      
Nationality, n (%)     
  Born in South Africa   468 (55.6) 
  Born outside of South Africa   349 (41.5) 
  Missing   25 (3.0) 
      
Employment status, n (%)     
  Employed   435 (51.7) 
  Not employed   386 (45.8) 
  Missing   21 (2.5) 
      
HIV-positive at first clinic visit, n (%)     
  Yes   611 (72.6) 
  No   229 (27.2) 
  Missing   2 (0.2) 
      
TB treatment*, n (%)     
  Yes   92 (10.9) 
  No   750 (89.1) 
IQR, interquartile range     
*Initiated TB treatment within one year from the time of testing HIV-positive. 
Patient retention by stage 
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Retention through each of stage of pre- and post-ART care is shown in Figure 1, 
while Figure 2 shows cumulative continuous retention through all stages of early HIV care. 
Among patients newly-diagnosed with HIV, the greatest attrition occurred in pre-ART care, 
with over 25% attrition at each of the three pre-ART stages (Figure 1) among those 
remaining in care at the beginning of each stage. Overall retention in pre-ART stage 1 was 
69.8% (95%CI 66.7%-72.9%) and included 32 subjects with no CD4 count, none of whom 
completed the stage. When limited to those with a CD4 count, retention was somewhat 
higher for those ineligible for ART than those eligible when testing HIV positive (76.5% vs. 
71.1%, respectively). The lowest proportion retained was in pre-ART stage 2 among those 
ART-ineligible, with only 57.4% (95%CI 49.5-65.0%) of those who returned for their initial 
CD4 results returning for a repeat CD4 test within one year. Median (IQR) CD4 value at 
repeat testing among those previously ineligible for ART was 424 cells/µl (337-570) with 
32.6% ART-eligible at their second CD4 staging. Retention after ART initiation was higher 
than during the pre-ART stages at 80.2% (95%CI 75.3-84.5%) between 0-6 months and 
95.3% (95%CI 91.7-97.6%) between 6-12 months.  
Of 544 patients who were ART-eligible when testing HIV-positive, the cumulative 
proportion who remained in care through 12 months on ART was only 36.9% (95%CI 33.0-
41.1%), and among 207 ART-ineligible patients, 43.0% (95%CI 36.4-49.8%) were retained 
within one year of initial CD4 staging (Figure 2). While attrition at each stage is substantial, 
overall attrition steadies over time. Among those completing a stage (or retained for pre-ART 
stage 2), the median (IQR) time to completing stage 1 (testing to completing staging) was 16 
days (9-28), stage 2 (completing staging until a repeat CD4 count) was 162 days (138-186), 
and stage 3 (ART eligibility to ART initiation) was 23 days (12-36), suggesting most patients 
who complete a stage do so within the defined time periods.  
 
 
 
 
 
Figure 4. Study profile of completion of key stages of early HIV care among 842 newly diagnosed HIV-positive patients at an 
HIV treatment program in South Africa. 
842 newly-diagnosed HIV-
positive patients
589/810 (72.7%) 
eligible for ART
32 missing initial CD4 
value did not complete 
CD4 staging
221/810 (27.3%) 
ineligible for ART
Pre-ART Stage 1: Completing 
CD4 staging within 3 months 
of HIV diagnosis
419/589 (71.1%,
95% CI: 67.4, 74.7%)
retained in Stage 1
Overall: 588/842 (69.8%, 
95% CI: 66.7, 72.9%) 
retained in Stage 1
169/221 (76.5%, 
95% CI: 70.5, 81.7%)
retained in Stage 1
12 transfers 14 transfers
Pre-ART Stage 2: If ineligible 
for ART, completing a second 
CD4 test within 12 months of 
first CD4 staging date
89/155 (57.4%, 
95% CI: 49.5, 65.0%) 
retained in Stage 2
29/89 (32.6%) eligible for 
ART per second CD4
60/89 (67.4%) ineligible 
for ART per second CD4
Pre-ART Stage 3: If eligible 
for ART, initiating ART within 
3 months of completing CD4 
staging
299/407 (73.5%, 
95% CI: 69.0, 77.6%)
retained in Stage 3
26/29 (89.7%, 
95% CI: 74.4, 97.3%) 
retained in Stage 3
11 transfers 2 transfers
Post-ART retention: 
Retention in care for 6 
months following ART 
initiation
231/288 (80.2%, 
95% CI: 75.3, 84.5%) 
retained for 0-6 months 
on ART
23/24 (95.8%, 
95% CI: 81.1, 99.9%)
retained for 0-6 months 
on ART
20 transfers
Post-ART retention: 
Retention in care for 12 
months following ART 
initiation
201/211 (95.3%, 
95% CI: 91.7, 97.6%) 
retained for 6-12 months 
on ART
N/A*
Stage completion is dependent on completing the prior stage in the time period specified. Patients eligible for ART per CD4 value at the time of HIV testing skip Pre-ART Stage 2 and move directly to Pre-ART Stage 3.
*12 month ART retention data not available by the end of data collection.
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Figure 5. Cumulative patient retention from HIV diagnosis through one year on ART 
for 544 HIV-positive patients eligible for ART, and one year after initial CD4 staging for 
207 HIV-positive patients ineligible for ART. 
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During the study period, 48 (5.7%, 95%CI 4.3-7.4%) patients died, however when we 
limit this to the 38.8% (n=327) of the sample with a valid South Africa ID, mortality doubles 
to 11.9% (95%CI 8.7-15.8%). Initial CD4 results are available for 46 (95.8%) of the 
deceased patients; of these, 87.0% were eligible for ART. Patients who died had a lower 
median initial CD4 count (105 cells/µl, IQR 49-169) than those who did not (225 cells/µl, IQR 
101-354), but did not differ from the overall cohort in terms of age, sex or TB treatment. 
Among ART-eligible patients, 2.5% (95%CI 1.5-4.1%) of patients in pre-ART stage 1 and 
3.9% (95%CI 2.4-6.2%) of patients in pre-ART stage 3 died. Following ART initiation, 2.4% 
(95%CI 1.1-4.8%) of patients died with less than six months on treatment and 1.0% (95%CI 
0.2-3.1%) with more than six months on ART. Among patients who were ART-ineligible, 
none died during pre-ART stage 1 and 2.7% (95%CI 1.1-5.6%) of patients in pre-ART stage 
2 died. Overall, 77.5% of ART-eligible patients who died did not initiate ART and the 
proportion of patients who died declined after ART initiation.  
 
Predictors of pre-ART and post-ART attrition 
Younger age (18-29 years) was associated with increased attrition in the pre-ART 
stages (aRR 1.56, 95%CI 1.21, 2.00), and possibly after ART initiation (aRR 1.27, 95%CI 
0.76, 2.13), compared to age 30-39 (Table 3). An initial CD4 <50 cells/µl predicted increased 
attrition before (aRR 1.51, 95%CI 1.08, 2.12) and after ART initiation (aRR 2.30, 95%CI 
1.15, 4.63), compared to an initial CD4 200-350 cells/µl. Male sex was associated with 
increased likelihood of attrition before ART (aRR 1.47, 95%CI 1.16, 1.87), but not after ART 
initiation (aRR 0.76, 95%CI 0.45, 1.28). Patients born outside of South Africa tended to fail 
to complete 12 months on ART (aRR 1.48, 95%CI 0.92, 2.40) compared to their South 
African counterparts. TB treatment was strongly associated with decreased attrition in the 
pre-ART stage (aRR 0.04, 95%CI 0.01, 0.27), but not following ART initiation (aRR 1.42, 
95%CI 0.79, 2.53). 
 
 
 
 
 
Table 3. Multivariate analysis of factors associated with patient attrition prior to ART and within the first 12 months 
after ART initiation among newly-diagnosed HIV-positive patients at an HIV treatment program in South Africa. 
 
Crude RR Adjusted RR Crude RR Adjusted RR
n (%)  (95% CI) (95% CI) n (%)  (95% CI) (95% CI)
Age at HIV testing
  18-29 years 96 (37.8) 1.57 (1.26, 1.94) 1.56 (1.21, 2.00) 18 (27.3) 1.55 (0.95, 2.52) 1.27 (0.76, 2.13)
  30-39 years 94 (26.7) 1 1 27 (20.0) 1 1
  40 years and older 48 (20.3) 0.65 (0.49, 0.86) 0.74 (0.52, 1.04) 12 (13.8) 0.62 (0.34, 1.11) 0.68 (0.36, 1.30)
First CD4 value
  <50 cells/µl 32 (31.4) 1.28 (0.93, 1.75) 1.51 (1.08, 2.12) 13 (28.9) 1.60 (0.94, 2.71) 2.30 (1.15, 4.63)
  50-199 cells/µl 69 (24.5) 0.94 (0.73, 1.21) 1.10 (0.82, 1.48) 31 (21.4) 1.18 (0.74, 1.88) 1.48 (0.81, 2.73)
  200-350 cells/µl 58 (25.8) 1 1 11 (11.6) 1 1
  >350 cells/µl 47 (23.4) 0.90 (0.67, 1.19) 0.90 (0.65, 1.26) NA† NA† NA†
Sex
  Female 116 (25.0) 1 1 37 (21.3) 1 1
  Male 122 (32.3) 1.29 (1.04, 1.60) 1.47 (1.16, 1.87) 20 (17.5) 0.83 (0.51, 1.35) 0.76 (0.45, 1.28)
Nationality
  Born in South Africa 119 (25.4) 1 1 25 (16.3) 1 1
  Born outside of South Africa 115 (33.0) 1.30 (1.04, 1.61) 1.11 (0.88, 1.40) 31 (25.6) 1.57 (0.98, 2.51) 1.48 (0.92, 2.40)
Employed
  Yes 119 (27.4) 1 1 29 (18.5) 1 1
  No 113 (29.3) 1.07 (0.86, 1.33) 1.07 (0.84, 1.36) 27 (22.1) 1.20 (0.75, 1.91) 1.13 (0.70, 1.81)
HIV-positive at first clinic visit
  Yes 185 (30.3) 1.31 (1.00, 1.71) 1.16 (0.86, 1.55) 43 (21.1) 1.33 (0.76, 2.34) 1.13 (0.64, 1.99)
  No 53 (23.1) 1 1 13 (15.9) 1 1
TB treatment†
  Yes 1 (1.1) 0.03 (0.00, 0.24) 0.04 (0.01, 0.27) 14 (25.5) 1.38 (0.81, 2.34) 1.42 (0.79, 2.53)
  No 237 (31.6) 1 1 43 (18.5) 1 1
RR, relative risk; CI, confidence interval; n (%) show proportion not retained in each category
Model is adjusted for all variables listed. Patients who transferred out of the clinic are removed from the analysis according to date of transfer.
*Post-ART model includes only patients who were initially eligible for ART and completed pre-ART stage 1 and pre-ART stage 3.
†Patients with CD4 values >350 are ineligible for ART.
Any pre-ART stage (n=842) Any post-ART stage (n=288)*
†Initiated TB treatment within one year from the time of testing HIV-positive.
4
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Discussion 
Retention in HIV care from the time of testing positive through lifelong ART treatment 
is critical for getting patients onto treatment promptly and preventing morbidity and mortality 
associated with disease progression. This study, one of the first to follow a consistent cohort 
of newly-diagnosed HIV-positive patients over a year through the various stages of pre-ART 
and early ART care, allowed us to summarize attrition throughout early HIV care. Our 
findings paint a stark picture—the proportion of patients ART-eligible when testing positive 
retained continuously in care through one year on ART was under 40%. This suggests that 
the majority of patients in our study continued to be at high risk of HIV-associated death and 
opportunistic infections despite knowing their HIV-positive status. 
This finding is consistent with a previous review of sub-Saharan African studies that 
estimated overall retention in pre-ART care to be 33%.37 One critical problem however with 
summarizing previous studies’ results is a lack of consistent definitions of retention and time 
periods over which retention was measured. Thus while many studies have previously 
documented high pre-ART30-32,34,35 and on-ART attrition15,26,27,60,65 at specific stages in care, 
our finding of substantial patient loss throughout the stages of early HIV care is one of the 
only studies to document this in a single cohort of ART-eligible and ineligible patients using 
standardized definitions.33 Studies that only investigate retention in disjointed cohorts are 
also unable to comment on the timing of attrition. We found that the pre-ART periods are a 
time of considerable loss, with over one-quarter of patients still in care lost at each stage.  
Our results also document the challenge of retention among patients ineligible for 
ART at the time of testing positive for HIV. Given that South Africa guidelines call for repeat 
CD4 testing every six months,45 the pre-ART stage 2 definition used gives patients ample 
time to return. Despite this, we found only 57.4% (95%CI 49.5-65.0%) of ART-ineligible 
individuals completed a repeat CD4 count within one year. This is true despite the fact that 
pre-ART services were available at the same clinic where the patient completed HIV testing 
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and CD4 staging and did not require visiting a separate location. While low, our retention 
results are higher than other recent studies from South Africa which have shown retention 
for patients not yet eligible for ART to be between 36.0% and 46.3%,32,34 and consistent with 
a meta-analysis result of 54.2% among ART-ineligible patients in sub-Saharan Africa.66 
The majority of patients in our study were ART-eligible when testing positive for HIV 
under the site’s threshold of a CD4 count ≤350 cells/µl. Among these eligible patients, for 
whom moving from HIV diagnosis to CD4 staging to ART initiation can be completed within 
two to eight weeks, attrition was greatest in pre-ART care. In just these few first weeks, 
patient attrition was 28.9% (95%CI 25.3-32.6%) from testing to CD4 staging and 26.5% 
(95%CI 22.4-31.0%) from ART eligibility to ART initiation. For those who initiated treatment, 
attrition 0-12 months after ART initiation remained high overall at 25.0% (95%CI 20.1-
30.4%), but most attrition occurred during 0-6 months on ART (19.8%, 95%CI 15.5-24.7%) 
and stabilized between 6-12 months on ART (4.7%, 95%CI 2.4-8.3%). This finding suggests 
that if patients have the motivation and support to complete the early milestones of CD4 
staging and ART initiation, they are likely to remain in care. Given the substantial proportion 
(28.9%) of ART-eligible patients who did not return for their second clinic visit to receive 
CD4 results, the challenge is to retain patients within the very first weeks of HIV care: from 
diagnosis through CD4 staging and ART initiation. Recognition of this challenge has 
encouraged new efforts to retain these patients, including offering point-of-care CD4 
technology and same-day ART initiation.67-69 
We identified several important predictors of patient attrition within the first year of 
HIV care (Table 3). Differing directions of estimates for predictors of pre-ART or post-ART 
attrition indicate that there may be different drivers of retention within each group at these 
unique stages that require specific, targeted interventions. For example, males had greater 
attrition in the pre-ART stages, but no gender difference was observed post-ART. Overall, 
our findings are consistent with other studies noting poorer retention among males27,32,35,36,60 
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and younger patients27,32,60 and highlight the need for interventions targeted to these specific 
groups, such as improved male-involvement approaches, youth-friendly services, mobile 
technology and others. Patients on TB treatment had much less likelihood of attrition during 
pre-ART stages, which differs from the results of an ART-eligible Durban cohort where 
newly-diagnosed TB patients experienced 76% greater attrition than TB-free patients.70 Our 
finding likely is due to regular follow-up at the clinic during TB treatment and active tracing of 
those who default TB treatment. After ART initiation, patients in our study were as likely, or 
possibly more likely, to drop out of care as those not on TB treatment, highlighting the 
importance of communicating the need for regular ART care beyond the TB treatment 
period. Being born outside of South Africa was associated with a nearly 50% increased 
likelihood of attrition following ART initiation, similar to Bygrave, et al,71 but in contrast to 
better retention in care among self-identified foreigners in South Africa found by McCarthy, 
et al.72 Witkoppen has a very high proportion of patients born outside of South Africa, which 
is becoming increasingly common in Johannesburg public-sector clinics, if not throughout 
the country.68,73 In addition to migration among immigrant patients, clinics should evaluate 
the potential for short- or long-term migration away from the clinic among immigrant and 
South African patients, and facilitate links to care and provide sufficient drug supply. 
Mortality in our study was low at 5.7%. Even though we used the South Africa 
Department of Home Affairs National Population Register to verify deaths, which has been 
shown to be 80% complete for adults with valid ID numbers,74 this estimate of overall 
mortality likely is underestimated as nearly half of our cohort was not South African and 
when we limited our mortality estimate tot only those with a valid South African ID, mortality 
doubled. It is difficult to compare our mortality estimate to findings of other studies since 
most focus only on either pre-ART or post-ART mortality. Among patients who died who 
were eligible for ART, we found that the majority of deaths occurred prior to ART initiation, 
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further emphasizing the importance of linkage to care during the critical pre-ART period and 
the need to fast-track patients with severe immunosuppression.  
Our results should be interpreted in light of their limitations. First, the generalizability 
of our results may be limited given that our data represent only one facility. Retention may 
have been higher than in most settings given the integration of HIV testing and care on-site. 
Previous studies suggest that moving from facility to facility for CD4 testing, ART initiation, 
etc., may encourage attrition.25,39 Second, retention may be underestimated as some 
patients considered lost in our analysis may have continued care and initiated treatment 
elsewhere. We only know of the intention to continue care elsewhere among patients who 
requested a transfer, a common limitation of studies investigating patient retention. Third, 
we defined attrition based on visit dates, which does not consider missed visits or treatment 
interruptions, which may overestimate the true amount of patient engagement in care. 
Finally, due to high patient drop-out throughout the study period, our sample size was 
reduced by the post-ART stages, limiting the precision of our regression analysis estimates 
for this period. Strengths of our study include a comprehensive dataset that allows for 
retention estimates from the point of testing HIV-positive through ART retention with few 
missing data. The study was conducted under routine clinical conditions and represents 
patient retention within a real-world scenario at one clinic. 
Our findings help to explicate the problem of attrition from HIV programs throughout 
the continuum of early HIV care. In our study, patient attrition was highest during the pre-
ART period, but our findings suggest that once patients initiate ART, they are more likely to 
be retained. These findings support the need for retention interventions that target patient 
loss from the very first visit when a patient learns their HIV-positive diagnosis.
 
 
 
 
 
 
 
CHAPTER 5 
LOSS TO FOLLOW-UP BEFORE AND AFTER DELIVERY AMONG WOMEN TESTING 
HIV-POSITIVE DURING PREGNANCY IN JOHANNESBURG, SOUTH AFRICA 
 
Introduction 
South Africa has a national antenatal HIV prevalence of 30.2%75 and more people 
living with HIV than any other country in the world.1 In an ongoing effort to improve care for 
pregnant women with HIV and to prevent mother-to-child transmission (PMTCT), and 
aligning with concurrent WHO revised PMTCT guidelines,76 South Africa’s 2010 HIV 
treatment guidelines called for lifelong ART to be initiated for all pregnant women with a 
CD4 value ≤350 cells/µl45 and PMTCT guidelines mandated AZT prophylaxis from 14 weeks 
of pregnancy.56 However, implementation of these guidelines remains inadequate, with 
pregnant women in South Africa commonly presenting for their first ANC visit well into their 
second trimester or later, delaying HIV diagnosis, AZT prophylaxis and lifelong ART 
initiation.77-79 
In addition to late presentation for ANC services, some studies suggest that pregnant 
women have poorer retention in HIV care than men and non-pregnant women.40,41 Retention 
in HIV care is paramount, as HIV-positive patients require routine management and daily 
adherence to ART once initiated,80 mortality is high among patients who drop out of ART 
programs,22,28 and HIV/AIDS contributes to nearly half (43.7%) of maternal deaths in South 
Africa, far overshadowing deaths due to other obstetric complications such as hemorrhage 
or sepsis.81 An analysis of nearly 30,000 women initiating antiretroviral therapy (ART) in 
South Africa found loss was 54% higher in pregnant than in non-pregnant women (aHR 
1.54; 95%CI 1.38-1.72), despite decreased mortality.42 The reasons for these differences 
49 
 
are still being identified, and may include lower rates of immunosuppression and a lack of 
perception of need for treatment,41,82 increased financial burden,41 travel or relocation during 
pregnancy,41,78,83 and stigma.78,84,85 In South Africa, antenatal coverage is widespread and 
nearly all births occur in healthcare facilities,86 but there is still great difficulty in ensuring an 
unbroken continuum of HIV care between antenatal care at a primary health clinic (PHC), 
labor and delivery at a hospital, and postnatal care and ongoing HIV care returning at the 
PHC.  
To date, investigations of retention in HIV care among pregnant women have 
provided an estimate of loss to follow-up between specific milestones, such as HIV testing to 
ART initiation,40,79,83 or ART initiation to between 6 months and 3 years on treatment,40-42 
without evaluating the impact of delivery on loss. While studies from the US demonstrate 
ART adherence often declines in the postpartum period compared to during pregnancy,87-90 
few studies have documented postpartum attendance in HIV care in sub-Saharan Africa in 
routine clinic settings.91 We hypothesize loss to follow-up may differ before and after delivery 
given that women’s motivations for seeking care may change during these time periods. 
This analysis of data from a cohort of newly-diagnosed HIV-positive pregnant women 
examines loss to follow-up through early stages of HIV care to better understand how loss to 
follow-up is influenced by delivery. 
 
Methods 
This study was conducted at Witkoppen Health and Welfare Centre (“Witkoppen”), a 
busy facility (8500 clinic visits per month) providing primary healthcare services to formal 
and informal settlements in northern Johannesburg, South Africa. Between January and 
June 2010, 300 pregnant women (≥18 years) tested HIV-positive for the first time at their 
first ANC visit at Witkoppen. We conducted a retrospective cohort study through file review 
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to assess attrition from pre-ART and on-ART care up to a minimum of 12 months after 
testing HIV-positive.  
 
HIV Care 
At Witkoppen, HIV care is integrated with antenatal care for pregnant women, with 
assessment for and initiation of ART occurring within ANC. In early 2010, Witkoppen began 
initiating all adult patients with CD4 ≤350 cells/µl onto ART, one year prior to national 
guidelines calling for this approach. We confirmed ART eligibility at the time of HIV testing 
for each subject through file review. During the time when the study was conducted, CD4 
testing was initiated at the same facility immediately following an HIV-positive test result, 
with a visit scheduled two weeks later to receive the CD4 results. For ART eligible patients, 
an ART initiation visit was scheduled two to four weeks after receiving the CD4 results. 
 
Antenatal and Postnatal Care 
Witkoppen offers antenatal and postnatal care, HIV testing and treatment on-site, as 
well as other primary healthcare and social welfare services. HIV testing at Witkoppen 
occurs during a woman’s first ANC visit and all HIV-positive pregnant women are given 
twice-daily zidovudine (AZT) starting as early as 14 weeks gestation, as called for in PMTCT 
guidelines.56 All women who receive antenatal care at Witkoppen are designated to deliver 
at Hillbrow Hospital in central Johannesburg (32.5 km from Witkoppen) or, if considered 
high-risk, at Charlotte Maxeke Johannesburg Academic Hospital (28.9 km). At the hospital, 
women not yet on lifelong ART are given intrapartum single-dose nevirapine and three-
hourly AZT, as well as postpartum single-dose tenofovir with emtricitabine for PMTCT. 
Newborns also start a six-week course of nevirapine syrup from birth.56 The hospitals do not 
routinely report delivery information back to Witkoppen. Following delivery, ANC patients 
return for postnatal care and HIV treatment services at Witkoppen for ten weeks and then 
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resume general adult care, all within the same facility and using the same clinic file. Mothers 
and infants make three postnatal care visits together: 3-7 days after delivery; six weeks after 
delivery for an infant polymerase chain reaction (PCR) HIV test; and 10 weeks after delivery 
for infant HIV PCR results. Women previously ineligible for ART should have a repeat CD4 
at the six-week postpartum visit. 
 
Timing of delivery 
Data on gestational age at HIV testing based on last menstrual period were available 
in most (88.3%) patient files while date of delivery was available in patient files for 39.7% of 
women. Thus, we determined a delivery date for 91% of women using either the actual date 
or an estimation assuming 40 weeks gestation. Women with no calculated delivery date 
(n=27, 9.0%) were excluded, leaving an analytic sample size of 273.  
 
Statistical Methods 
Patient characteristics are described using proportions and 95% confidence intervals 
(95%CI) for categorical variables, and medians and interquartile ranges (IQR) for continuous 
variables. We examine retention among pregnant women in two ways. First, we report 
retention through several stages of pre- and post-ART care within the antenatal and 
postnatal periods using counts and proportions with 95%CI. The first stage for all patients is 
completing CD4 staging, including results notification, prior to delivery. For those ART-
eligible, subsequent stages include ART initiation prior to or after delivery, completing a 
clinic visit after delivery, and six months retention on ART. For ART-ineligible patients, 
subsequent stages include returning for a clinic visit after delivery and receiving a repeat 
CD4 test after delivery. A diagram of these stages is presented in Figure 1. Retention is 
defined as completing each stage and is determined using clinic visit data. Patients who 
transfer are noted and removed from the analysis at the start of the stage in which they 
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transferred. Cumulative retention analyses exclude patients who transferred during the 
antenatal (n=6) and postnatal (n=11) periods.  
Second, we use time-to-event analysis to assess loss to follow-up before and after 
delivery by estimating person-time in the antenatal and postnatal periods. Loss to follow-up 
is defined as not returning to the clinic within a minimum of one month after the last 
scheduled visit. For the antenatal period, person-time began accruing at testing HIV-positive 
and ended at the first of the following three events: 1) delivery, 2) loss to follow-up or 3) 
transfer to another facility prior to delivery. For women remaining in care at the beginning of 
the postnatal period, person-time began accruing at delivery and ended at the earliest of: 1) 
six months after delivery; 2) loss to follow-up; or 3) transfer after delivery. No deaths were 
reported during the antenatal and postnatal time periods studied, so these represent all 
possible known outcomes. We examined predictors of loss within the antenatal and 
postnatal periods using Cox proportional hazard regression and report adjusted hazard 
ratios (aHR) and 95%CI.  
 Ethical approval for this study was granted by the Human Research Ethics 
Committee of the University of the Witwatersrand and exemption was given by the 
Public Health-Nursing IRB at the Office of Human Research Ethics at the University of 
North Carolina at Chapel Hill.  
 
Results  
Clinical and demographic characteristics at HIV testing of the 273 pregnant women 
are summarized in Table 4. The median (IQR) age at the first ANC visit was 27 years (24-
31) and the median CD4 count at the time of HIV testing was 357 cells/µl (238-500). Overall, 
almost half of the cohort (44.7%) was born outside of South Africa, most notably in 
Zimbabwe (89.3% of those foreign-born).  
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Table 4. Characteristics of the study participants (N=273). 
 
 
  
Patient characteristic 
Continuous variables, median (IQR)
Age at HIV testing 27 (24-31)
First CD4 value (cells/µl) 357 (238-500)
Weeks of gestation at first ANC visit 26 (21-30)
Categorical variables, n (%)
Age at HIV testing
  18-24 years 78 (28.6%)
  25-29 years 98 (35.9%)
  30 years and older 97 (35.5%)
First CD4 value
  <50 cells/µl 4 (1.5%)
  50-199 cells/µl 48 (17.6%)
  200-350 cells/µl 83 (30.4%)
  >350 cells/µl 136 (49.8%)
  Missing 2 (0.7%)
Nationality
  Born in South Africa 143  (52.4%)
  Born outside of South Africa 122  (44.7%)
  Missing 8 (2.9%)
Employment status
  Employed 97  (35.5%)
  Not employed 167  (61.2%)
  Missing 9 (3.3%)
Gestation at first ANC visit
  ≤20 weeks 59 (21.6%)
  >20 weeks 214 (78.4%)
IQR, interquartile range
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The median (IQR) gestational age at first ANC visit was 26 weeks (21-30) and the 
median (IQR) time from HIV testing to delivery was 3.1 months (2.1-4.1). AZT monotherapy 
as part of PMTCT was almost universally implemented. During pregnancy 98.0% received at 
least one 30-day supply of AZT, all but one of whom (99.7%) started AZT on the day of 
testing HIV-positive.  
 
Retention during antenatal care 
Figure 6 shows retention of pregnant women through early HIV care, contingent on 
completing earlier stages. Roughly half of all women were ART-eligible at the time of testing; 
median (IQR) CD4 at HIV testing was 244 cells/µl (171-299) among ART-eligible and 500 
cells/µl (420-599) among ART-ineligible women. Completing CD4 staging prior to delivery 
was high at 84.9% (95%CI: 80.2-88.8%) overall, and varied little by ART eligibility (87.1% 
vs. 82.7%). Of those who were ART-eligible and who completed CD4 staging prior to 
delivery (n=115), most (80.9%; 95%CI: 72.9-87.3%) went on to initiate lifelong ART prior to 
delivery. These women spent a median (IQR) of 27 days (17-41.5) from HIV testing to ART 
initiation and a median (IQR) 9.5 weeks (5.1-14.2) on ART prior to delivery. Of the remaining 
22 ART-eligible women who completed CD4 staging but did not initiate ART prior to delivery, 
most (n=18, 81.8%) never returned for ART initiation, one returned but left before initiation, 
one required further counseling, one refused ART, and one completed the initiation visit but 
was rescheduled to return for initiation a week later and did not return. Of all 139 ART-
eligible women, 66.9% (95%CI: 58.8-74.3%) initiated treatment prior to delivery.  
 
 
 
 
 
Figure 6. Patient retention before and after delivery among 271 recently-diagnosed HIV-positive ANC patients. 
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Retention after delivery 
The proportion of patients returning for at least one visit after delivery was highest 
among those who were eligible for ART and initiated treatment prior to delivery (n=85) at 
75.3% (95%CI: 65.3-83.6%) with most of these women (82.8%; 95%CI: 72.1-90.6%) 
retained in ART care for at least six months. Though the numbers of women who completed 
CD4 staging and were eligible for but did not initiate ART were small (n=22), only 31.8% 
(95%CI: 15.1-53.1%) returned at any point after delivery, and less than half of those who did 
(42.9%; 95%CI: 12.3-78.4%) initiated ART within six months of delivery. The picture was 
much different for those ineligible for ART at the time of testing positive. Among those ART-
ineligible who completed CD4 staging (n=115), less than half (46.7%, 95%CI: 37.4-56.2%) 
returned for any visits after delivery. Of these 50 women, only half (52.0%, 95%CI: 38.2-
65.5%) received a repeat CD4 count after delivery.  
 
Cumulative retention in HIV care 
Figure 7 shows cumulative retention for ART-eligible women from HIV testing 
through delivery and six months on ART as well as for ART-ineligible women through a post-
delivery repeat CD4 count. Cumulatively, less than half (40.5%, 95%CI: 32.3-49.0%) of 
ART-eligible patients who tested HIV-positive during pregnancy completed CD4 staging, 
initiated ART prior to delivery, returned after delivery and completed six months on ART. 
Cumulative retention was even lower among those ineligible for ART at the time of HIV 
testing: only 21.1% (95%CI: 14.6-29.0%) of patients ineligible for ART continued in care to 
the point of a repeat CD4 count after delivery.  
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Figure 7. Cumulative patient retention from HIV diagnosis through six months on ART 
for 131 HIV-positive ANC patients eligible for ART, and through repeat CD4 testing 
after delivery for 123 HIV-positive ANC patients ineligible for ART. 
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Ineligible for ART per CD4 at time of testing HIV-positive (n=123)
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The median (IQR) person-time contributed in the antenatal period was 2.8 months 
(1.7-3.9) and 4.5 months (1.5-6.0) in the postnatal period. Using time-to-event analysis and 
analyzing all women regardless of ART eligibility at the time of testing, 20.5% (95%CI: 16.0-
25.6%) of women were lost to follow-up prior to delivery. Among women in care at delivery, 
47.9% (95%CI: 41.2-54.6%) were lost within six months after delivery, for a cumulative loss 
to follow-up of 57.5% (95%CI: 51.6-63.3%).  
Table 5 presents the results of multivariate analysis of factors associated with loss 
within the antenatal and postnatal time periods. Presenting late for the first ANC visit (after 
20 weeks gestation) was associated with twice the likelihood of loss prior to delivery after 
adjusting for age, initial CD4 count and nationality (aHR 2.00; 95%CI 1.00, 4.02) but late 
presentation was not associated with loss during the postnatal period (aHR 1.09; 95%CI 
0.65-1.83). ART-ineligibility at the time of HIV testing based on a CD4 count >350 cells/µl 
was strongly associated with loss to follow-up following delivery (aHR 3.30; 95%CI: 1.95-
5.58), while pregnant women age 30 years and older were less likely to be lost after delivery 
(aHR 0.49; 95%CI: 0.30-0.81). Our results suggest that women born outside of South Africa 
may be more likely to be lost after delivery (aHR 1.36; 95%CI: 0.90-2.06) than women born 
in South Africa.
 
 
 
 
 
Table 5. Multivariate analysis of factors associated with loss to follow-up before and after delivery among 273 newly-
diagnosed HIV-positive antenatal patients. 
n (%)*
Crude HR 
(95% CI)
Adjusted HR 
(95% CI) n (%)*
Crude HR 
(95% CI)
Adjusted HR 
(95% CI)
Age at HIV testing
  18-24 years 19 (24.4) 1.26 (0.66, 2.40) 1.25 (0.64, 2.42) 31 (54.4) 0.96 (0.61, 1.52) 0.91 (0.57, 1.43)
  25-29 years 18 (18.4) 1 1 45 (57.7) 1 1
  30 years and older 19 (19.6) 0.94 (0.54, 1.63) 1.08 (0.55, 2.11) 25 (32.9) 0.50 (0.31, 0.82) 0.49 (0.30, 0.81)
First CD4 value
  <200 cells/mm3 10 (19.2) 1.12 (0.51, 2.47) 1.24 (0.56, 2.78) 16 (41.0) 1.71 (0.87, 3.36) 1.72 (0.87, 3.42)
  200-350 cells/mm3 16 (19.5) 1 1 18 (27.3) 1 1
  >350 cells/mm3 28 (20.4) 0.95 (0.51, 1.75) 1.03 (0.55, 1.94) 67 (63.2) 3.00 (1.78, 5.05) 3.30 (1.95, 5.58)
Nationality
  Born in South Africa 31 (21.7) 1 1 48 (44.9) 1 1
  Born outside of South Africa 25 (20.5) 1.05 (0.62, 1.78) 0.99 (0.57, 1.72) 52 (54.2) 1.33 (0.90, 1.97) 1.36 (0.90, 2.06)
First ANC visit >20 weeks gestation
  No 14 (23.7) 1 1 18 (40.9) 1 1
  Yes 42 (19.6) 2.11 (1.07, 4.19) 2.00 (1.00, 4.02) 83 (49.7) 1.29 (0.77, 2.14) 1.09 (0.65, 1.83)
HR, hazard ratio; CI, confidence interval
Loss  to fol low-up is  defined as  not returning to the cl inic within ≥1 month after the last scheduled vis i t; antenatal  care period is  defined as  HIV testing date to del ivery date; postnatal  
  care period is  defined as  del ivery date to 6 months  after del ivery.
Adjusted models  are adjusted for a l l  variables  l i s ted. 
* Proportion lost to fol low-up during the period for each category l i s ted.
Antenatal care period (n=273) Postnatal care period (n=211)
5
9
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Discussion 
Pregnant women diagnosed with HIV during antenatal care require effective care 
interventions to ensure the prompt initiation of PMTCT and ART, but also must be linked to 
HIV care that is sustainable beyond the point of delivery. We found that overall loss to 
follow-up within 13 months of HIV testing among pregnant women recently diagnosed with 
HIV was staggeringly high at 57.5% (95%CI: 51.6-63.3%). Unlike studies that begin 
reporting loss to follow-up at ART initiation, our findings span the period from testing HIV-
positive through both the pre-ART and early post-ART periods, periods of high attrition. 
Patients who initiate ART have already successfully been retained through several visits, 
and thus, may be more inclined to continue in care. Few reports exist of retention of all 
patients – both ART eligible and ineligible. Our loss to follow-up proportion, which includes 
this early loss, is much higher than the 12%-32% among pregnant women after six months 
to three years on ART reported elsewhere which only focuses on the on-treatment period.40-
42   
Our analysis also suggests that the focus on cumulative loss to follow-up among 
pregnant women is missing important trends over time with implications for when to 
intervene. Loss to follow-up prior to delivery was much lower than after delivery (20.5% vs. 
47.9%). The antenatal period is a time of reasonable compliance with HIV care, likely 
because women are already attending care for another reason for which they have 
motivation to continue. Our results suggest many women are not returning to the PHC after 
delivery. Among HIV-positive pregnant women, the challenge is ensuring HIV care extends 
beyond the period of pregnancy and continues for the lifetime of the mother. In South Africa, 
infants are to accompany their mothers to the first three postnatal care visits, so failure to 
attend these visits also suggests a failure to link infants to postnatal care, including PCR 
testing for HIV. 
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In addition to a high rate of loss to follow-up, we also found pregnant women 
presented for their first ANC visit and HIV testing well after the recommended gestational 
age of 14 weeks for AZT initiation. The median gestational age at HIV testing of 26 weeks in 
our study matched that found by Stinson et al.,79 and represents delayed PMTCT efforts. 
Half of the pregnant patients in our cohort were ART-eligible at their first ANC visit, yet 
despite the overall trend of late presentation, 66.9% (95%CI: 58.8-74.3%) of those eligible 
initiated ART prior to delivery. The median time from first visit to ART initiation of 27 days 
indicates that patients are being initiated promptly after the first visit, but as the median time 
on ART is 9.5 weeks, they are not presenting early enough to obtain maximal effectiveness 
of ART for PMTCT, which is reached around 13-15 weeks duration prior to delivery.57,58 The 
median duration on ART prior to delivery in our study is consistent with findings of 7.6-10.7 
weeks in other studies in South Africa.77-79,92 Additionally, nearly one-third (31.1%, 95%CI 
25.7-41.2%) of ART-eligible women should have initiated before delivery but did not. 
Recognition of the problem of late presentation to ANC care and its impact on delayed ART 
initiation, as well as poor linkage to care prior to ART, has spurred interest in rapid or same-
day ART initiation among pregnant women using point-of-care CD4 testing.93 
South African ANC patients receive a government-mandated ANC card at their first 
ANC visit, and must present it at the hospital labor ward prior to delivery. There has been 
speculation that women only attend one ANC visit to get this card but do not return for 
additional care. Our data do not support this idea. Among pregnant women in our cohort, 
15.1% failed to complete CD4 notification (i.e. attended only one clinic visit), which is half 
the proportion (30.2%) of non-pregnant adults who did not complete CD4 staging during this 
same period.94 Our finding of sufficient linkage to care among pregnant women is consistent 
with that of Kranzer et al., who found CD4 completion was highest among antenatal care 
patients in Cape Town when compared to patients of other clinic services.32 This suggests 
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that many women are making repeat visits while pregnant but then have high rates of loss 
after delivery. 
In our study women who presented late for their first ANC visit (>20 weeks gestation) 
were twice as likely to be lost prior to delivery (aHR 2.00, 95%CI 1.00-4.02), underscoring 
the difficulty of retaining patients who are initially slow to seek care. Three South Africa-
based studies identified fear of HIV testing/diagnosis, confusion over pregnancy status, 
transport limitations, lack of perceived benefit, and clinic booking delays as common 
reasons for late presentation among ANC patients,82,95,96 highlighting the multi-level barriers 
that can prevent timely access to and retention in care among pregnant women. Patients 
with higher CD4 counts (>350 cells/µl) who were ineligible for ART were more likely to be 
lost postpartum (aHR 3.30; 95%CI 1.95-5.58), emphasizing the importance of retention 
during pre-ART care. South Africa’s PMTCT guidelines call for repeat CD4 testing after 
delivery, but only 22.6% of ART-ineligible women received a repeat CD4 count. Witkoppen 
has a very high proportion of patients born outside of South Africa, as is now common in 
PHCs throughout Johannesburg.68,73 These patients may be at greater risk of loss to follow-
up after delivery (aHR 1.36; 95%CI 0.90-2.06), likely because of frequent mobility among 
this group. 
Our findings must be considered in light of the study’s limitations. First, we do not 
know why women ceased care at Witkoppen. Under half (45.2%) of the women who were 
lost received at least one follow-up phone call. We reviewed the files of 84 pregnant patients 
who were lost to follow-up whom the clinic had made at least one attempt to contact. Over 
half (52.3%) were unreachable because their cell phone was off or out of service and 20.2% 
were found to have moved out of the area, usually outside Johannesburg’s Gauteng 
Province. This may indicate that women return to rural homes41,78,83 – whether in South 
Africa or a neighboring country – either immediately prior to or following birth. While 
migration around delivery is typically short-term, it disrupts the continuity of care, which likely 
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impairs adherence to ART. We also do not have data on ART adherence, which can affect 
PMTCT, nor do we have information on the care of the infants. 
Second, we do not know if patients who drop out of care at Witkoppen continue in 
care at other facilities, perhaps in a rural facility or outside South Africa, except for those 
who request a formal transfer. While this is a limitation shared by most studies of loss to 
follow-up, it is important to note that loss to follow-up in this study reflects ceasing care at 
one clinic only, but one that was selected for study due to close integration of antenatal 
care, postnatal care and HIV services. We also cannot link to hospital data to confirm 
delivery. More research is needed into ways to improve linkages across treatment sites and 
ways to improve patient movement between sites (e.g. providing sufficient supply of 
antiretrovirals). 
Finally, our study data, which were collected retrospectively, were limited to those 
routinely collected in the patient files, but with very few missing data. Our findings regarding 
timing of first ANC visit and linkage to care among ANC patients are consistent with 
previously reported studies from other regions of South Africa,32,79 suggesting that our 
results are generalizable to other clinics throughout South Africa. 
Our study highlights much room for improvement in the provision of HIV care of 
pregnant women. We found that pregnant women presented late for their first ANC visit, 
initiated ART too late to achieve maximal PMTCT effectiveness, and had high rates of drop 
out around the time of delivery. Pregnant women likely have different motivation for 
attending healthcare services than non-pregnant adults, and likewise, different reasons why 
they may become lost. Efforts must be increased to better understand the intentions of 
pregnant women for seeking healthcare after delivery, understanding their motivations for 
ceasing HIV care, and improve linkages to care after delivery. 
 
 
 
 
 
 
 
CHAPTER 6 
INITIATING ART WHEN PRESENTING WITH HIGHER CD4 COUNTS RESULTS IN 
REDUCED LOSS TO FOLLOW-UP UNDER SOUTH AFRICA’S 2010 REVISED 
ANTIRETROVIRAL THERAPY GUIDELINES 
 
Introduction 
South Africa’s national antiretroviral therapy (ART) program, launched in 2004, is the 
world’s largest,1 with 1.8 million individuals initiated on ART by mid-2011.4 Initially, the 
threshold for ART eligibility in the national guidelines for adult ART initiation was set at a 
CD4 cell count below 200 cells/µl or a WHO Stage IV clinical condition.97 In late 2009, the 
WHO revised their guidelines by increasing the threshold for eligibility for ART in resource-
limited settings to ≤350 cells/µl.43,44 In August 2011, South Africa officially adopted this 
policy.46 It has been estimated that this policy expanded eligibility to an additional 1.06 
million (95%CI: 0.88-1.29m) ART-naïve adults with CD4 values 200-349 cells/µl.4  
Patients who initiate ART with a CD4 above 200 cells/µl are at reduced risk of death 
and serious opportunistic infections including tuberculosis, as demonstrated in developed 
countries,98-100 a randomized trial in Haiti,50 and observational studies in sub-Saharan 
Africa.47-49 However, if patients initiate treatment before perceiving the clinical necessity, 
gains from positive clinical outcomes from earlier treatment may be offset by increases in 
patient loss to follow-up.13 To date, only one study has reported the effect of initiation at 
higher CD4 counts on loss to follow-up under routine early initiation (≤350 cells/µl) within 
sub-Saharan Africa and found 39% reduced loss among those initiating at CD4 cell counts 
>200 cells/µl versus ≤200 cells/µl (aHR 0.61, 95%CI: 0.43-0.87).47  
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Witkoppen Health and Welfare Centre (Witkoppen) is an NGO-operated clinic 
serving a primarily poor population from formal and informal settlements in northern 
Johannesburg, South Africa. In March 2010, a year before the national policy was enacted, 
Witkoppen began ART initiation for all adult patients at the higher threshold of ≤350 cells/µl. 
This provides a unique opportunity to examine the impact of initiating treatment among 
patients presenting at higher CD4 counts on patient loss to follow-up under routine care.  
Methods 
We created a retrospective cohort of all adult (≥18 years) ART-naïve patients 
initiating ART at Witkoppen during April-December 2010 who presented with a baseline CD4 
value eligible for ART (≤350 cells/µl). We excluded 29 patients missing a baseline CD4 
value, leaving 1430 for analysis. Data were extracted from the clinic’s electronic patient 
record system (TherapyEdge-HIV™) in May 2012, allowing all subjects time to experience a 
12-month outcome. Patients who provided a South African ID number (n=685, 47.9%) were 
matched to the National Population Register of the South African Department of Home 
Affairs in August 2011 to identify deaths. 
We sought to estimate the effect of initiating ART with a CD4 count 201-350 versus 
≤200 cells/µl on loss to follow-up (primary outcome) in the first 12 months after ART 
initiation. We defined loss as not returning to the clinic within 3 months of the patient’s last 
scheduled visit. For loss to follow-up, person-time began accumulating three months after 
ART initiation (when patients became at risk for loss) and excluded 50 patients who died or 
transferred in the first three months. Person-time ended at death within 12 months, or the 
earliest of 12 months of follow-up, loss to follow-up or transfer. We defined baseline CD4 
count (≤200 and 201-350 cells/µl) as the temporally last measure between six months prior 
and seven days after ART initiation and grouped patients into those who presented and 
initiated ART with a lower (≤200 cells/µl) or higher (201-350 cells/µl) baseline CD4 value. 
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We produced crude Kaplan-Meier curves of time to loss by CD4 group. We used Cox 
proportional hazards regression to estimate the association of CD4 category and 12-month 
loss to follow-up and report adjusted hazard ratios (aHR) and 95% confidence intervals 
(95%CI). We also evaluated the impact of death on estimates of loss using a competing 
risks analysis and report the subdistribution hazard ratio (sHR) and 95%CI. 
We identified pregnancy at ART initiation as an effect measure modifier of the 
relation between CD4 count and loss to follow-up by stratifying estimates of the risk of loss 
by CD4 group, gender and pregnancy. Based on prior knowledge and change-in-estimate 
evaluation, we adjusted models for age, nationality, employment and prevalent TB. The 
study was approved by institutional review boards at the University of North Carolina at 
Chapel Hill and the University of the Witwatersrand. 
Results 
Among the 1430 patients, nearly half (48.0%) presented with a CD4 201-350 cells/µl 
at ART initiation (Table 6). Median (IQR) baseline CD4 by group was 105 cells/µl (55-154) 
versus 268 cells/µl (239-307). The higher CD4 count group was more likely to be <30 years 
old (31.7% vs. 24.5%) and female (75.7% vs. 63.4%), partly because there were more 
pregnant women (19.2% vs. 10.6%) in the higher CD4 group due to routine antenatal HIV 
testing. The low CD4 count group had more tuberculosis at ART initiation (16.7% vs. 5.7%).  
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Table 6. Characteristics of the study participants by baseline CD4 group (N=1430). 
 
  
Patient characteristic 
     Total
     (N=1430)
CD4 ≤200 cells/µl
(n=743, 52.0%)
CD4 201-350 cells/µl
(n=687, 48.0%)
Sex, n (%)
   Female 991 (69.3) 471 (63.4) 520 (75.7)
   Male 439 (30.7) 272 (36.6) 167 (24.3)
Age at HIV testing, median (IQR) 34.3 (29.3, 41.2) 35.2 (30.0, 42.2) 33.3 (28.7, 39.9)
Age at HIV testing, n (%)
  18-29 years 400 (28.0) 182 (24.5) 218 (31.7)
  30-39 years 625 (43.7) 327 (44.0) 298 (43.4)
  40 years and older 405 (28.3) 234 (31.5) 171 (24.9)
First CD4 value (cells/mm3), median (IQR) 195 (103, 266) 105 (55, 154) 268 (239, 307)
First CD4 value, n (%)
  <50 cells/µl 169 (11.8) 169 (22.8) 0 (0.0)
  50-100 cells/µl 182 (12.7) 182 (24.5) 0 (0.0)
  101-200 cells/µl 392 (27.4) 392 (52.8) 0 (0.0)
  201-350 cells/µl 687 (48.0) 0 (0.0) 687 (100.0)
Nationality, n (%)
  Born in South Africa 969 (67.8) 504 (67.8) 465 (67.7)
  Born outside of South Africa 461 (32.2) 239 (32.2) 222 (32.3)
Employment status, n (%)
  Employed 736 (51.5) 391 (52.6) 345 (50.2)
  Not employed 694 (48.5) 352 (47.4) 342 (49.8)
TB at ART initiation, n (%)
  No 1267 (88.6) 619 (83.3) 648 (94.3)
  Yes 163 (11.4) 124 (16.7) 39 (5.7)
Pregnant at ART initiation, n (%)
  No 1219 (85.2) 664 (89.4) 555 (80.8)
  Yes 211 (14.8) 79 (10.6) 132 (19.2)
IQR, interquartile range
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Within one year of ART initiation, 15.5% (95%CI: 13.0-18.2%) versus 12.7% (95%CI: 
10.3-15.3%) were lost among those in the lower versus the higher CD4 group, respectively 
(Figure 8). Among non-pregnant females, we found a 42% reduction in loss to follow-up 
among women initiating ART at higher versus lower CD4 cell counts (aHR 0.58; 95%CI: 
0.37-0.91) (Table 7). Males who initiated ART at higher CD4 counts were also at reduced 
risk of loss to follow-up compared to males who started ART at CD4 count ≤200 cells/µl 
(aHR 0.74; 95%CI: 0.44-1.23). However among pregnant women there was no association 
between CD4 category and loss to follow-up (aHR 0.95; 95%CI: 0.55-1.67). Additionally, 
younger adults (age 18-29 years) were 38% more likely to become lost to follow-up 
compared to adults age 30-39 years (aHR 1.38, 95%CI: 1.00-1.92), and unemployed 
patients were 51% (aHR 1.51, 95%CI: 1.34-2.00) more likely to become lost to follow-up.  
Estimates differed little when accounting for death as a competing risk. Figure 8 shows the 
gender variation in loss to follow-up: males were more likely to be lost than non-pregnant 
females and women pregnant at ART initiation were most likely to be lost.   
During the first year of ART care, 29 patients (1.9%; 95%CI: 1.3-2.7%) died and 44 
acquired TB (3.1%; 95%CI: 2.3-4.1%). Patients initiating ART at CD4 values 201-350 
cells/µl were at much lower risk of death (aHR 0.34; 95%CI: 0.13-0.84) and incident TB 
(aHR 0.44; 95%CI: 0.23-0.85) than those with CD4 ≤200 cells/µl.  
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Figure 8. Kaplan-Meier estimates of time to loss to follow-up by baseline CD4 value 
(top) and by baseline CD4 by gender/pregnancy at ART initiation status (bottom). 
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Table 7. Multivariate analysis of factors associated with patient loss to follow-up one 
year after ART initiation at an HIV treatment program in South Africa (N=1430). 
  
Crude HR Adjusted HR Competing risk sHR*
n (%)  (95% CI) (95% CI) (95% CI)
Non-pregnant female, CD4 ≤200 cells/µl  50/369 (13.6) 1 1 1
Non-pregnant female, CD4 201-350 cells/µl 33/380 (8.7) 0.61 (0.39, 0.94) 0.58 (0.37, 0.91) 0.59 (0.38, 0.91)
Male, CD4 ≤200 cells/µl 45/261 (17.2) 1 1 1
Male, CD4 201-350 cells/µl 22/164 (13.4) 0.74 (0.44, 1.23) 0.74 (0.44, 1.23) 0.74 (0.45, 1.24)
Pregnant at ART initiation, CD4 ≤200 cells/µl 20/76 (26.3) 1 1 1
Pregnant at ART initiation, CD4 201-350 cells/µl 32/130 (24.6) 0.93 (0.53, 1.62) 0.95 (0.55, 1.67) 0.96 (0.56, 1.67)
Age at HIV testing
  18-29 years 74/383 (19.3) 1.50 (1.10, 2.06) 1.38 (1.00, 1.92) 1.39 (1.00, 1.91)
  30-39 years 83/605 (13.7) 1 1 1
  40 years and older 45/392 (11.5) 0.83 (0.58, 1.20) 0.93 (0.64, 1.35) 0.93 (0.64, 1.34)
Nationality
  Born in South Africa 139/931 (14.9) 1 1 1
  Born outside of South Africa 63/449 (14.0) 0.95 (0.70, 1.27) 0.82 (0.61, 1.11) 0.83 (0.61, 1.12)
Employment status
  Employed 87/716 (12.2) 1 1 1
  Unemployed 115/664 (17.3) 1.50 (1.14, 1.99) 1.51 (1.34, 2.00) 1.50 (1.13, 1.99)
TB at ART initiation
  Yes 22/155 (14.2) 0.97 (0.63, 1.52) 1.01 (0.64, 1.59) 1.00 (0.63, 1.59)
  No 180/1225 (14.7) 1 1 1
HR, hazard ratio; CI, confidence interval; n (%) show proportion lost to follow-up in each category
Models are adjusted for all variables listed
Loss to follow-up is defined as not returning ≥3 months after the last scheduled visit; the HR models exclude 50 patients 
   who died or transferred prior to 3 months follow-up (N=1380)
*The competing risk subdistribution hazard ratio (sHR) model includes all 1430 patients and assesses patient loss to follow-up 
   in the presence of the competing risk of death
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Discussion 
This is the first study from a routine clinical setting in South Africa to demonstrate patients 
can be initiated on ART at higher CD4 counts without increasing patient attrition. We found 
42% (aHR 0.58; 95%CI: 0.37-0.91) reduced risk of loss to follow-up among non-pregnant 
females and 26% (aHR 0.74; 95%CI: 0.44-1.23) reduced risk among male patients who 
initiated ART at CD4 counts 201-350 cells/µl compared to those ≤200 cells/µl. This result is 
in concert with a 39% reduced loss among those initiating at CD4 cell counts >200 cells/µl 
versus ≤200 in Lesotho.47 However our study highlights substantial variation by gender in 
reduced risk at initiating at higher CD4 cell counts. The association of initiating at higher 
CD4 counts was greatest among non-pregnant females and males, and null among 
pregnant women. Patient loss is a major challenge to providing effective HIV care and our 
results suggest that expanding ART eligibility to patients with higher baseline CD4 values 
can be done without increasing loss. 
 We found that loss to follow-up among males of both CD4 groups was substantially 
higher than non-pregnant females who initiate at CD4 201-350 cells/µl (Figure 8), which 
suggests the need for specific retention interventions targeted to males. Loss to follow-up 
among women pregnant at ART initiation was the highest of any gender group, but 
interestingly, baseline CD4 did not substantially affect loss among pregnant women, 
possibly because loss was already so high. High loss to follow-up among pregnant women 
recently has been reported in other studies within South Africa,41,42,60 and is particularly 
concerning since HIV is the largest cause of maternal mortality in South Africa.81   
 Additionally, our results confirm the considerable reductions in mortality and incident 
tuberculosis throughout the first year of ART seen among patients who present for care and 
initiate ART with a higher CD4 count versus those who present with advanced 
immunosuppression. These findings correspond with those of several studies in resource-
limited settings that observed significantly reduced risk of death and opportunistic infections 
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when initiating treatment at higher CD4 values47-50 and support South Africa’s decision to 
revise its ART guidelines in 2011 to align with WHO recommendations. 
Our study has several strengths. The unique study site allowed us to examine the 
impact of initiating at higher CD4 values within the context of routine, clinical care.  
Additionally, our analysis assessed the potential for the competing risk of death to bias our 
associations, but found little evidence of an important influence. We reduced the likelihood 
of death being misclassified as loss to follow-up by validating deaths using South Africa’s 
national death registry. However, the registry only includes patients with a valid South 
African ID number (47.9%) and included only deaths through data export in August 2011. 
We conducted a sensitivity analysis restricted only to patients with a valid South African ID 
number but this did not change the size of our effect or our conclusions. 
Limitations to our analysis include use of data obtained from a single site and 
therefore findings may not be generalizable to all public-sector settings within South Africa 
or health care centers in other regions. As with most retention studies, we cannot know if a 
patient continued care at another facility due to unlinked data at facilities. Thus, loss to 
follow-up in this study must be understood as lost to the facility where ART was initiated. It is 
important not to interpret our results as evidence for when to start ART (i.e. a comparison of 
whether or not to initiate patients when their CD4 count first falls ≤350 or defer until CD4 
counts reach <200). Our results only pertain to what happens to patients once they are 
diagnosed and initiate ART at their initial presentation CD4 value.  
 Our results show that adult, non-pregnant patients presenting for care and initiating 
ART at 201-350 cells/µl have reduced loss to follow-up than those presenting and initiating 
ART at ≤200 cells/µl, with significant variation by gender and pregnancy status. These are 
the first results to show South Africa’s 2011 expansion of ART treatment guidelines can be 
enacted without increasing attrition among patients initiating at higher CD4 values. As data 
become available from more sites that adopted the policy of initiating ART at higher CD4 cell 
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counts, it will be important to perform similar evaluations at other sites in South Africa and 
other countries. Such information will be invaluable to national HIV/AIDS programs looking 
for guidance about the implications of earlier ART initiation, and may inform future 
expansions of the ART treatment criteria in South Africa.
 
 
 
 
  
 
 
 
 
 
CHAPTER 7 
CONCLUSIONS 
Summary of findings 
  To fulfill Aim 1, we produced two manuscripts that investigated retention in care at 
critical stages of early HIV care among recently-diagnosed patients. In Chapter 4, we found 
that among non-pregnant adults at Witkoppen, the pre-ART period was the time of highest 
attrition with over 25% attrition at each pre-ART stage. In Chapter 5, we focused our 
analysis on pregnant women diagnosed with HIV during antenatal services and found 
considerable pre-ART loss among those ART-eligible, but notably less than the non-
pregnant adults analyzed in Chapter 4. Among ART-eligible non-pregnant adults, 71.1% 
(95%CI 67.4-74.7%) completed CD4 staging within three months of HIV diagnosis and 
73.5% (95%CI 69.0-77.6%) of those initiated ART within three months of CD4 staging. By 
comparison, among ART-eligible pregnant women, 82.7% (95%CI 75.8-88.3%) completed 
CD4 staging before delivery and 80.9% (95%CI 72.9-87.3%) of those initiated ART before 
delivery. However, overall loss to follow-up among pregnant women 13 months after testing 
HIV-positive was higher at 57.5% (95%CI 51.6-63.3%) compared to 49.6% (95%CI 46.3-
53.0%) in non-pregnant adults. Our time-to-event analysis of LTFU prior to and post-delivery 
showed a marked difference in the periods: 20.5% (95%CI 16.0-25.6%) lost prior to delivery 
and, among those still in care at delivery, 47.9% (95% CI 41.2-54.6%) after. These results 
suggest that many pregnant women remain in care during pregnancy but then drop out in 
great numbers after delivery. 
  Both manuscripts fulfilling Aim 1 highlighted poor retention among patients ineligible 
for ART at the time of testing HIV positive. Among non-pregnant adults, 57.4% (95%CI 49.5-
75 
 
65.0%) completed a second CD4 test within 12 months of testing HIV-positive. Among 
pregnant women, retention among ART-ineligible patients was even lower: only 46.7% 
(95%CI 37.4-56.2%) attended at least one clinic visit after delivery and half of those who 
returned (52.0%, 95%CI 38.2-65.5%) received a repeat CD4 test. Cumulative retention from 
HIV testing to repeat CD4 testing among non-pregnant adults ineligible for ART was 44.3% 
(95%CI 37.5-51.2%) and 21.1% (95%CI 14.6-29.0%) among pregnant women ineligible for 
ART. 
  In the analysis for Aim 2 (Chapter 6), we found that among adults (non-pregnant and 
pregnant) initiating ART, LTFU one year post-initiation was 14.6% (95%CI 12.8-16.6%). This 
is consistent with our results of Chapter 4, which found attrition 0-6 months after ART 
initiation at 19.8% (95%CI 15.5-24.7%) and 6-12 months at 4.7% (95%CI 2.4-8.3%). 
Retention was improved after ART initiation, which likely is due to several factors. First, in 
order to initiate ART, patients must first complete at least one, but usually two, additional 
visits. A patient who returns for all visits required to initiate ART already has a pattern of 
clinic attendance and is more likely to remain in care than those who do not. Additionally, 
ART provides rapid improvements in health, wellbeing and reduces mortality, so by initiating 
ART, it is possible that these patients’ health has improved so that they are more likely to be 
able to make it to the clinic. By highlighting the difference in pre-ART and post-ART 
retention as we have through these three manuscripts, we have identified pre-ART as the 
time of greatest attrition and demonstrated that studies that track adherence from the point 
of ART initiation are likely to substantially underestimate overall loss. 
  Furthermore, in Chapter 6, we found reduced LTFU among non-pregnant females 
and males initiating ART at 201-350 cells/µl than those who presented for care and initiated 
ART at CD4 counts ≤200 cells/µl, after controlling for confounding variables. This is the first 
paper to report on this outcome within the context of routine ART initiation at CD4 values 
201-350 cells/µl within a primary healthcare clinic in South Africa. We also reported lower 
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mortality (aHR 0.34, 95%CI 0.13-0.84) and incident tuberculosis (aHR 0.44, 95%CI 0.23-
0.85) among patients initiating at the higher CD4 group, which are consistent with other 
recent studies.47,48,50,101  
 
Public health significance 
  Our findings and other studies throughout Southern Africa showing failure to 
complete early critical milestones of HIV care among patients accessing public sector care 
suggest that linkages to care between newly-diagnosed HIV-positive patients and long-term, 
sustainable HIV care are not sufficient and requires intensified efforts and novel 
approaches.30-32,34-37 While patient attrition may not weaken the public healthcare system 
itself – after all, when patients drop out of care there are fewer to treat – it is a major public 
health concern. If patients who are considered lost to follow-up at clinics are indeed not 
seeking HIV care elsewhere, then they are at substantial risk of opportunistic infections and 
death, and those who have initiated ART but default treatment are also at risk of acquiring 
drug resistance. If patients do eventually return to care, many will do so with more advanced 
immunosuppression, requiring additional interventions and/or treatment, greater resource 
expenditure and substantial healthcare costs, if hospitalized. Thus, patient attrition limits the 
impact of the national HIV program and its ability to deliver healthy lives to HIV-infected 
individuals. 
  On a more positive note, our findings of reduced LTFU, death and incident TB 
among patients initiating ART at CD4 counts 201-350 cells/µl, as compared to ≤200 cells/µl, 
suggest that the recent expansion of eligibility criteria for ART initiation in South Africa has 
the potential to translate into substantial clinical benefit for HIV-infected South Africans, if 
those who have higher CD4 counts seek care before advanced immunosuppression. This, 
coupled with our finding that patients who initiate ART typically have better retention and 
patients deemed ineligible for ART have the worst retention, suggest that expanding 
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treatment guidelines to initiate ART at higher CD4 values may result in improved retention 
overall. Since this is the first study to report data under routine conditions in South Africa, it 
will be important to re-evaluate the effect of initiating at higher CD4 values as additional data 
become available from across the country, and also from other countries as ART eligibility 
expands.   
  Throughout these analyses, we have identified some important factors associated 
with patient attrition at various stages of early HIV care. Compared to non-pregnant females, 
male sex was associated with attrition in any pre-ART stage in Chapter 4 (aRR 1.47, 95%CI 
1.16-1.87) and 12-month LTFU (aHR 1.53, 1.10-2.13) post-initiation in Chapter 6. Younger 
age (18-29 years vs. 30-39 years) also is a factor associated with attrition in any pre-ART 
stage (aRR 1.56, 95%CI 1.21-2.00) and 12-month LTFU post-initiation (aHR 1.38, 95%CI 
1.00-1.92). We found no significant association with patient nationality and LTFU in any of 
our analyses.  
  One of the biggest predictors of attrition that we found is also one of the most 
concerning. Pregnant women experienced attrition in substantial numbers, as shown in 
Chapter 5. In the multivariate analysis for Chapter 6, women pregnant at ART initiation were 
more than three times as likely to be LTFU after 12 months on ART than non-pregnant 
women initiating at CD4 values 201-350 cells/µl. The public health implications of this are 
profound, including increased risk of death and morbidity for the mother and increased 
incidence of orphanhood, increased risk of mother-to-child transmission of HIV, and 
incomplete care for the infant. 
 
Future research directions 
While a body of qualitative research on barriers to retention exists, further research 
that specifically examines pregnant women’s reasons for dropping out of care is needed 
urgently. The phenomenon of pregnant women traveling around the time of delivery is 
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widely known anecdotally within clinics and among migration experts, and has been 
suggested in the literature,41,78,83 but is not well documented and examined. We must 
determine whether these suspected travel patterns actually exist and use both quantitative 
and qualitative research methods to better understand this pregnancy-associated migration 
and its impact on maternal and infant health. Follow-up studies to confirm linkages to care 
among new mothers also are missing in the literature. Better data systems that would link 
patients among all public health facilities would significantly improve researchers’ ability to 
determine if a patient – pregnant or otherwise – is engaged in care elsewhere or lost to 
follow-up. 
Recognition of incomplete linkages to care among recently-diagnosed HIV-positive 
individuals has led to interventions that aim to reduce the number of visits and days required 
before a recently-diagnosed patient can begin ART. Such interventions include rapid, point-
of-care CD4 testing with same-day results,68,69 and faster initiation of ART among pregnant 
women.93 Two previously-published studies have explored a case management intervention 
to improve linkages to HIV care, both based in the US,102,103 and research on 
implementation of this type of intervention in the South African setting is needed. 
In recent years, programs incorporating the use of mobile phone and text message 
technology in health promotion, including ART adherence, have appeared throughout the 
world.104-106 Such technology also may assist with reducing missed visits and facilitating a 
link from HIV testing to ART initiation. Lastly, ART initiation and monthly procurement may 
eventually expand to mobile vans to access hard-to-reach populations in South Africa, but 
research into the implementation and evaluation of such programs are lacking.107   
 
Conclusion 
Retention among recently-diagnosed HIV-positive patients is a serious concern in 
South Africa. Our findings help to identify the key time points when patients are most at-risk 
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of dropping out of care, establishing that the greatest amount of attrition is in the pre-ART 
period, particularly for patients who are not yet eligible for ART. This study adds to the 
growing body of literature on early loss to follow-up among HIV-positive individuals. The first 
year of care is critical for establishing a connection to lifelong care and we must better 
understand the specific nuances of periods subsequent to HIV diagnosis.  We also must 
measure the impact of broadening ART treatment guidelines so that appropriate policies 
and interventions can be developed to retain patients across the continuum of care from 
diagnosis to treatment while expanding treatment options. In summary, the findings not only 
serve an academic purpose, but also have practical value. Identifying the time periods most 
associated with LTFU, and the impact of early initiation on LTFU within a routine clinic 
setting, may impact HIV and ART policy within the public healthcare sector in South Africa 
and other sub-Saharan African countries. By contributing to the literature of patient 
retention, we can quicken the transition from estimating and reporting retention to designing 
and implementing targeted interventions aimed at the groups most likely to be at risk of 
dropping out during the first year of HIV care. 
  
 
 
 
 
Table A.1. Summary table of pre-ART retention in HIV care literature
 
Citation
Year 
published Location
Sample 
size/population Study design
Follow-up 
period LTFU definition Exposure(s) Outcome(s) Statistical methods Results Conclusion
1
Bassett IV, Chetty S, Wang B, 
Mazibuko M, Giddy J, Lu Z, Walensky 
RP, Freedberg KA, Losina E. Loss to 
follow-up and mortality among HIV-
infected people co-infected with TB 
at ART initiation in Durban, South 
Africa. J Acquir Immune Defic Syndr. 
2012 Jan 1;59(1):25-30.
2012 Sinikithemba 
HIV clinic, 
Durban, South 
Africa
1034 ART-naïve 
patients 
undergoing ART 
literacy training
Observational 
cohort
1 year Missing >3 mos 
and unable to be 
reached by 
phone or 
confirmed dead 
after multiple 
attempts
1) Newly-
diagnosed with TB 
by culture
2) Already on TB 
treatment at 
enrollment
3) TB-free
LTFU and mortality Cox PH regression modeling, 
adjusted for gender, age, 
baseline CD4, smoking status, and 
OI history
aHR for death or LTFU for pts 
newly-diagnosed with TB vs 
those TB-free: 1.76 (95% CI: 1.20, 
2.60)
Trend toward increased death 
and LTFU among those already on 
TB tx vs TB-free: HR 1.24, (95% CI: 
0.84, 1.82)
Patients newly-diagnosed with TB 
were 76% more likely to die or be 
LTFU (all-cause attrition) than 
those TB-free at enrollment
2 Boyles TH, Wilkinson LS, Leisegang R, 
Maartens G. Factors influencing 
retention in care after starting 
antiretroviral therapy in a rural South 
african programme. PLoS One. 2011 
May 3;6(5):e19201.
2011 Eastern Cape, 
South Africa 
(rural)
1803 adult 
patients (>19) 
initiating ART
Observational 
cohort
Median 13.3 
months (IQR: 
5.4-25)
No patient 
contact for >6 
months before 
the end of study 
period
Age, sex, baseline 
CD4, baseline viral 
load, 
pregnant/inpatient
/on TB tx at time of 
ART initiation
LTFU, death, transfer, 
alive and on 
treatment
Cox PH regression modeling, 
adjusted for competing risks 
(LTFU or dying)
Overall patient outcomes: 71.5% 
still in care, 11.1% died, 6.5% 
LTFU, 10.9% transferred.  Higher 
LTFU (13.6%) for pregnant women 
and higher death for those 
initiating ART as inpatients 
(32.4%) and on TB tx (16.3%).  Risk 
of LTFU was associated with 
higher CD4 count, younger age, 
inpatient status and pregant at 
ART initiation. Receiving >6 mos 
pre-ART care was associated with 
decreased LTFU.
Low LTFU overall, but initiating 
ART while pregnant or inpatient 
may require extra counseling to 
avoid LTFU.  Pre-ART care may be 
protective against ART LTFU.
3 Brennan AT, Maskew M, Sanne I, Fox 
MP. The importance of clinic 
attendance in the first six months on 
antiretroviral treatment: a 
retrospective analysis at a large 
public sector HIV clinic in South 
Africa. J Int AIDS Soc. 2010 Dec 
7;13:49. 
2010 Johannesburg, 
South Africa
4476 adult (≥18) 
patients 
initiating ART
Observational 
cohort
53 months 
maximum, 21 
months 
minimum
Not having been 
to the clinic for 
at least four 
months
Missing a 
scheduled clinic 
visit by at least 7 
days (ARV or 
medical)
1) mortality, 2) LTFU, 
3) immunologic 
response, 4) virologic 
suppression
Log-binomial regression 
(adjusted for age, sex, WHO stage 
III/IV, BMI, baseline hemoglobin 
and CD4, and first ART regimen) 
to estimate RR of missing a visit 
on CD4 and VL by 6 mos on Art.  
Cox PH models to estimate HR of 
mortality and LTFU by missed visit 
status
Adjusted HR associated with 
missing ≥3 medical visits: 
Death: 4.74  (95% CI: 1.39, 16.2)
2.98 (95% CI: 1.10, 8.14)
More missed visits were 
associated with increased risk of 
death and LTFU over 12 mos of 
follow-up.
Patients who miss multiple visits 
in the earliest period of 
treatment but remain in care are 
at increased risk of poorer ART 
outcomes
4 Brinkhof MW, Pujades-Rodriguez M, 
Egger M. Mortality of patients lost to 
follow-up in antiretroviral treatment 
programmes in resource-limited 
settings: systematic review and meta-
analysis. PLoS One. 2009 Jun 
4;4(6):e5790.
2009 South Africa, 
Malawi, 
Uganda, 
Zambia, 
Botswana, 
Ethiopia, 
Kenya, 
Tanzania, Mali 
and India
6420 adult post-
initiation LFTU 
patients from 
17 studies
Systematic 
review and 
meta-analysis
Varied Varied Study 
characteristics: 
urban/rural setting; 
missed last visit by 
>3 mos; method of 
tracing; percentage 
of patients LTFU 
included in survey; 
percentage of 
patients traced and 
retrieved during 
survey
Number of patients 
who could be traced, 
number found to be 
alive and the number 
who had died
Random-effects meta-analysis on 
the logit scale; random effects 
meta-regression for associations 
between study characteristics and 
mortality in patients LTFU
Vital status of 63% of patients 
could be ascertained
Combined mortality from random 
effects meta-analysis: 40% (95% 
CI: 33%, 48%); if looking only at 
public ART programs in sub-
Saharan Africa: 46% mortality 
(95% CI: 39%, 54%)
ART programs with high rates of 
LTFU and poor ascertainment of 
mortality may underestimate true 
rates of mortality
Mortality in LTFU patients is much 
higher than mortality usually 
reported in the first year of ART 
and mortality was highest in first 
6 mos of LTFU
5 Bygrave H, Kranzer K, Hilderbrand K, 
Whittall J, Jouquet G, Goemaere E, 
Vlahakis N, Triviño L, Makakole L, 
Ford N. Trends in loss to follow-up 
among migrant workers on 
antiretroviral therapy in a community 
cohort in Lesotho. PLoS One. 2010 Oct 
8;5(10):e13198.
2010 Morjia, 
Lesotho
1185 adult (≥18) 
patients 
initiating ART
Observational 
cohort
Minimum 1 
year, 
maximum 2 
years
No clinic visit for 
at least 3 months 
at the end of the 
observation 
period
Migrant status 
(migrant = crossed 
into SA for work)
LTFU, death, transfer, 
study end
K-M estimates of outcomes by 
migrant status.  Poisson 
regression models of the 
association between migrant 
status and LTFU or death, 
adjusted for age (≤40 or >40), sex, 
baseline CD4 (≤200 or >200) and 
TB at initiation.  Poisson model 
uses Lexis expansion splitting 
time into 0-3 mos, 3-6 mos, 6-12 
mos and >12 mos on ART.
12% of cohort were migrant 
workers
Rates of LTFU were similar for 
migrants/non-migrants at 3 mos, 
but much higher for migrants at 
later points (RR, 95% CI): 
3-6 mos: 2.78 (1.15, 6.73)
6-12 mos: 2.36 (1.18, 4.73)
>12 mos: 6.69 (3.18, 14.09)
LTFU among migrant workers as 
time on ART progressed.  
Theorized that this could be the 
"health migrant" effect -- 
returning to work in SA after 
feeling better on ART.
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6 Cornell M, Grimsrud A, Fairall L, Fox 
MP, van Cutsem G, Giddy J, Wood R, 
Prozesky H, Mohapi L, Graber C, Egger 
M, Boulle A, Myer L; International 
Epidemiologic Databases to Evaluate 
AIDS Southern Africa (IeDEA-SA) 
Collaboration. Temporal changes in 
programme outcomes among adult 
patients initiating antiretroviral 
therapy across South Africa, 2002-
2007. AIDS. 2010 Sep 10;24(14):2263-
70.
2010 Western Cape, 
Free State, 
Gauteng and 
KZN, South 
Africa
44,177 adult 
(≥16) patients 
initiating ART
Observational 
cohort
Minimum 1 
year, 
maximum 6 
years (median 
1.27 years)
Last patient 
contact was 
more than 6 
months before 
database closure
Year of ART 
initiation, baseline 
CD4 (<50 vs >200, 
ref.)
Mortality, LTFU and 
program retention
K-M estimates of time to death, 
LTFU and overall program 
retention by year of enrollment.  
Cox PH regression models, 
stratified by cohort, adjusted for 
age, year of enrollment, baseline 
CD4, WHO stage and VL.
Adjusted HR (CD4 as exposure):
Mortality: 5.85 (95% CI: 4.47, 7.65)
LTFU: 0.83 (95% CI: 0.76, 0.91)
With each successive year of 
enrollment, risk of mortality 
decreased.
LTFU risk was higher in those with 
higher baseline CD4, but the 
association did not persist when 
WHO staging was added to the 
model.
6 mo LTFU: 9%; 36 mo LTFU: 30%
High levels of LTFU are a threat to 
the success of the national ART 
program.
7 Cornell M, Myer L, Kaplan R, Bekker 
LG, Wood R. The impact of gender 
and income on survival and retention 
in a South African antiretroviral 
therapy programme. Trop Med Int 
Health. 2009 Jul;14(7):722-31.
2009 Cape Town, 
South Africa
2196 adult (≥16) 
patients 
initiating ART
Observational 
cohort
Maximum 4.5 
years, median 
1 year
Started ART but 
absent from 
clinic >3 months
Gender (women = 
ref.), income (some 
vs. none, ref.)
Mortality and LTFU Cox PH regression modeling, 
adjusted for gender, age, 
baseline CD4, WHO stage, VL, 
income
Adjusted HR (income as 
exposure):
LTFU: 0.53 (95% CI: 0.37, 0.77)
Men with no income have higher 
mortality than women with no 
income: 1.89 (95% CI: 1.25, 2.86)
Highest mortality in first year, 
particularly first 4 month on tx.  
Significantly higher mortality rate 
among males did not hold after 
adjustment.  
6% of patients LTFU at 1 year.  
Income generation is strongly 
protective against LTFU and 
mortality (in men).  High 
mortality in men due to late 
presentation.
8 Fox MP, Brennan A, Maskew M, 
MacPhail P, Sanne I. Using vital 
registration data to update mortality 
among patients lost to follow-up 
from ART programmes: evidence 
from the Themba Lethu Clinic, South 
Africa. Trop Med Int Health. 2010 
Apr;15(4):405-13.
2010 Johannesburg, 
South Africa
1037 patients 
eligible for ART 
and LTFU
Cross-
sectional
--- Missed any clinic 
appointment by 
at least 3 months 
after scheduled 
visit date
Age, last CD4, last 
BMI, last Hb, 
months on ART 
before being lost
Mortality among 
LTFU patients
Difference in proportion for 
mortality before and after vital 
registration system; K-M 
estimates of crude predictors of 
death; Cox PH regression of 
adjusted predictors of death
Prior to updating mortality using 
vital registration system, 4.2% of 
LTFU were known dead; after 
updating: 10.9%.  Strongest 
predictors of death among LTFU: 
last CD4 (HR 3.4, 95% CI: 2.3, 5.0) 
and last BMI <17.5 (HR 2.4, 95% CI: 
1.8, 3.1)
High mortality among pts LTFU in 
South Africa.  The probability of 
death among the LTFU was over 
30% at the end of 1 year.  Tracing 
programs still miss a substantial 
number of deaths among those 
considered LTFU.
9 Fox MP, Rosen S. Patient retention in 
antiretroviral therapy programs up to 
three years on treatment in sub-
Saharan Africa, 2007-2009: systematic 
review. Trop Med Int Health. 2010 
Jun;15 Suppl 1:1-15.
2010 Sub-Saharan 
Africa (16 
countries)
226,307 
patients 
initiating ART 
within 39 
cohorts
Systematic 
review and 
meta-analysis
At least 6 
months follow-
up required
LTFU varied by 
study; in meta-
analysis, 
attrition = 
patients who 
died or were 
LTFU; retention = 
1 - attrition
Age, gender, 
baseline CD4, 
duration of follow-
up (≤12 mos vs >12 
mos), patient 
payment required 
(y/n), sector 
(public/private/oth
er), year of cohort 
initiation (<2004 vs 
≥2004)
All-cause patient 
attrition from ART 
programs
Summarized retention rates from 
39 cohorts using random-effects 
meta-analysis using a Freeman & 
Tukey arc-sin transformation of 
the retention proportions and 
standard errors; presented point 
estimates of retention and 95% 
CI; extrapolated retention rates 
for all studies through 3 years 
using a best-case, worst-case and 
midpoint scenario; linear 
regression modeling to examine 
predictors of retention
Retention estimated at 86.1% at 
six months, dropped to 72.3% by 
36 months
Predictors of lower retention 
rates at 6 mos: CD4 count <100, 
median age <36, having <60% 
females in cohort; predictors of 
lower retention rates at 12 mos: 
median age <36, CD4 count <100 
and cohort follow-up ≤12 mos
Overall attrition may be slowing 
as ART programs scale-up and 
mature
Programs with lower median CD4 
and fewer females are at higher 
risk of patient attrition
Need to prioritize patient tracking 
and vital status ascertainment 
and track patient transfers
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10 Kaplan R, Orrell C, Zwane E, Bekker 
LG, Wood R. Loss to follow-up and 
mortality among pregnant women 
referred to a community clinic for 
antiretroviral treatment. AIDS. 2008 
Aug 20;22(13):1679-81.
2008 Gugulethu, 
South Africa
1677 women 
initiating ART, 
about 15% of 
whom were 
pregnant at 
time of 
initiation
Observational 
cohort
3 years No clinic 
attendence for 
12 or more 
weeks
Preganant at the 
time of ART 
initiation
LTFU and mortality 
during the first year 
of ART
Multivariate analysis; K-M 
estimates of association between 
pregnancy and LTFU
Women pregnant at ART 
initiation  were more likely to be 
LTFU than non-pregnant women  
(aRR: 2.1, 95% CI: 1.4, 3.1) but 
mortality was not associated with 
pregnancy
Younger women (<25 yrs) were 
more likely to be LTFU than 
women >35 (aRR: 2.2, 95% CI: 1.3, 
3.6) 
Pregnant women are at higher 
risk of LTFU during the pre-ART 
and post-ART periods, despite 
being at lower risk of mortality 
during these times. 
This finding highlights the need 
for programmatic interventions to 
address retention in care for this 
patient population.
11 Myer L, Cornell M, Fox M, Garone D, 
Wood R, Prozensky H, Ndirangu J, 
Keiser O, Boulle A and IeDEA-
Southern Africa Collaboration. Loss 
to follow-up and mortality among 
pregnant women and non-pregnant 
women initiating ART: South Africa. 
CROI 2012. Oral abstract #22.
2012 5 South 
African 
cohorts (IeDEA 
Collaborative)
29,653 women 
initiating ART, 
of whom 1956 
(6.6%) were 
pregnant
Observational 
cohort
Min 6 months, 
maximum 7 
years
Unclear Preganant at the 
time of ART 
initiation
LTFU and mortality 
during the first year 
of ART
Product-limit estimations of 
proportion alive or LTFU during 
the first year of ART; Cox PH 
regression modeling
Women pregnant at ART 
initiation were much likely to be 
LTFU than non-pregnant women 
(19% vs 11%; aHR: 1.54, 95% CI: 
1.38, 1.72)
Pregnant women less likely to die 
in the first year of treatment than 
non-pregnant women (3% vs 9%)
Women who start ART during 
pregnancy have lower mortality 
but much greater LTFU than non-
pregnant women. 
Interventions must promote 
retention of women intiating ART 
during pregnancy.
12 Sanne IM, Westreich D, Macphail AP, 
Rubel D, Majuba P, Van Rie A.  Long 
term outcomes of antiretroviral 
therapy in a large HIV/AIDS care clinic 
in urban South Africa: a prospective 
cohort study. J Int AIDS Soc. 2009 Dec 
17;12:38.
2009 Johannesburg, 
South Africa
7583 patients 
initiating ART
Observational 
cohort
Maximum 4 
years, median 
20.3 months
More than 3 
months for a 
scheduled visit 
and unable to 
trace
Baseline CD4 (≤50 
vs >200, ref.)
Mortality, LTFU, CD4 
response, viral 
suppression
K-M estimates of retention in 
care; Cox PH regression modeling 
Crude HR: 
Mortality: 4.87 (95% CI: 2.94, 8.09)
LTFU: 1.18 (95% CI: 0.96, 1.43)
Monthly attrition rate: 1.43 in first 
12 mos
Death rate in first 90 days of 
HAART: 8.4 per 100 py
Over 4 years, 16.4% LTFU
Low overall mortality, LTFU 
highest in first year of care.  Short-
term estimations of LTFU may 
underestimate retention in care.
13 Toro PL, Katyal M, Carter RJ, Myer L, 
El-Sadr WM, Nash D, Abrams EJ; MTCT-
Plus Initiative. Initiation of 
antiretroviral therapy among 
pregnant women in resource-limited 
countries: CD4+ cell count response 
and program retention. AIDS. 2010 
Feb 20;24(4):515-24.
2010 MTCT-Plus 
program sites: 
Cameroon, 
Cote d'Ivoire, 
Kenya, 
Mozambique, 
Rwanda, 
South Africa, 
Uganda, 
Zambia and 
Thailand
2229 treatment-
naïve patients 
initiating ART, 
of whom 605 
were pregnant 
women (27.1%)
Observational 
cohort
Minimum 6 
months, 
maximum 4 
years
At least 3 failed 
attempts to 
trace a patient 
following a 
missed 
appointment or 
failure to attend 
the facility for >6 
mos after the 
last visit or lab 
test
Gender and 
pregnancy
LTFU and mortality Survival analysis: mortality-
specific rates, K-M estimates of 
retention in care
At censoring, 3.5% mortality (1.8 
per 100 py) and 8.6% LTFU (4.6 per 
100 py)
No significant difference in 
mortality and LTFU by gender or 
pregnancy status
Overall retention in care was high 
(85%) and did not differ 
significantly by gender or 
pregnancy status. The healthier 
status of MTCT-Plus patients, as 
well as heavy emphasis on 
psychosocial support, likely 
contributed to lower mortality 
risk and high retention rates
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14 Wang B, Losina E, Stark R, Munro A, 
Walensky RP, Wilke M, Martin D, Lu 
Z, Freedberg KA, Wood R. Loss to 
follow-up in a community clinic in 
South Africa--roles of gender, 
pregnancy and CD4 count. S Afr Med 
J. 2011 Apr;101(4):253-7.
2011 One NGO HIV 
clinic near 
Rustenburg 
(NW), South 
Africa
925 adult (>14 
years) patients 
initiating ART
Observational 
cohort
Minimum 6 
months, 
maximum 2.5 
years
Clinic-based 
definition: 
failure to return 
for scheduled 
visit or med pick-
up within 6 mos 
of ART initiation; 
Data-based 
definition: no 
recorded 
information in 
the database on 
a patient 
returning for a 6-
mo visit
Gender, pregnancy 
and CD4 count
LTFU (analysis used 
the clinic-based 
definition)
K-M estimates of retention in 
care; Cox PH regression modeling 
Cumulative probability of LTFU at 
6 mos: pregnant women (12%), 
non-pregnant women (6%), men 
(3%)
Crude HR:
Age ≤30: HR 2.14 (95% CI: 1.05, 
4.38)
Pregnancy: HR 3.75 (95% CI: 1.53, 
9.16)
Pregnant women with baseline 
CD4 ≤200 had the highest risk of 
LTFU of all after 6 mos on ART: HR 
6.06, 95% CI: 2.30, 16.71
Gender and pregnancy status 
were significantly associated to 
LTFU and pregnant women had 
the highest risk of LTFU of all 
patients.
8
3
 
 
 
Table A.2. Summary table of post-ART retention in HIV care literature 
 
  
1 Amuron B, Namara G, Birungi J, 
Nabiryo C, Levin J, Grosskurth H, 
Coutinho A, Jaffar S.  Mortality and 
loss-to-follow-up during the pre-
treatment period in an antiretroviral 
therapy programme under normal 
health service conditions in Uganda. 
BMC Public Health. 2009 Aug 
11;9:290.
2009 Jinja, 
southeast 
Uganda
2483 patients 
eligible for ART 
at one 
rural/semi-
urban NGO 
clinic
Observational 
cohort
Median: 351 
days
Could not be 
traced for follow-
up after about a 
year (median 
351 days) from 
point of ART 
eligibility
Gender, age, 
baseline CD4, WHO 
stage
Completed screening 
and on ART, died, on 
ART with another 
provider, alive and 
not on ART, LTFU
Logistic regression of association 
between exposures and starting 
ART
K-M estimates of survival time
Poisson regression modeling of 
the association between baseline 
CD4 and mortality
88% of eligible patients returned 
for the 2nd visit (median interval: 
14 days) and were told of 
eligibility; 74% returned for 3rd 
visit (median interval: 33 days) 
and started ART
Not completing screening 
associated with low baseline CD4 
and male sex
After about a year, patients who 
didn't start ART were followed-up 
at home: 28% had died, 30% self-
reported being on ART with a 
different provider, 25% were 
alive and chose not to be on ART 
and 17% were LTFU
Mortality rate during screening 
procedures was very high
About 1/4 did not complete 
screening and start ART.  Of 
these, almost half only came to 
one visit and never learned their 
eligibility, and half learned their 
eligibility but did not come back
Patients presented with 
advanced HIV stage 
Almost half of patients said they 
did not start treatment due to 
transport costs
2 Bassett IV, Regan S, Chetty S, Giddy J, 
Uhler LM, Holst H, Ross D, Katz JN, 
Walensky RP, Freedberg KA, Losina E. 
Who starts antiretroviral therapy in 
Durban, South Africa?... not 
everyone who should. AIDS. 2010 
Jan;24 Suppl 1:S37-44.
2010 Durban, South 
Africa
538 adult (≥18) 
ART-eligible pts 
(CD4 <200)
Observational 
cohort
12 months Missed visit + 
not returning 
after 3 phone 
call attempts
Baseline 
characteristics 
(gender, 
employment, CD4, 
known HIV 
family/friend, site of 
care, distance to 
clinic, transport 
mode, ever TB, HIV 
testing history)
ART initiation within 
12 months of 
enrollment in the 
STIAL study 
Multivariate Poisson regression, 
adjusting for gender, location of 
employment, known HIV-
infected family/friend, site of 
care, baseline CD4 and HIV testing 
history (ever/never)
K-M estimate of time from HIV 
testing to ART initiation, stratified 
by gender 
Difference of proportions 
(mortality)
Adjusted RR (95% CI):
Male: 1.32 (1.14, 1.54)
Known HIV-infected 
family/friend: 1.35 (1.08, 1.68)
20% mortality (highest among 
those with CD4 <50); most deaths 
were pre-initiation
Median time to ART start was 6.6 
months
Less than half eligible started ART 
within 12 mos
Men are more likely to fail to 
initiate ART, as are those pts with 
a friend or family member known 
to be HIV-positive.
No association between failure to 
initiate and age and baseline CD4.
3 Bassett IV, Wang B, Chetty S, 
Mazibuko M, Bearnot B, Giddy J, Lu Z, 
Losina E, Walensky RP, Freedberg KA. 
Loss to care and death before 
antiretroviral therapy in Durban, 
South Africa. J Acquir Immune Defic 
Syndr. 2009 Jun 1;51(2):135-9.
2009 Durban, South 
Africa
501 adult (≥18) 
ART-eligible pts 
(CD4 <200)
Observational 
cohort
6 months ART-eligible 
patients 
scheduled for 
ART training who 
did not start ART 
and were lost to 
care ≤3 mos of 
final ART 
training visit
Baseline 
characteristics 
(gender, 
employment, CD4)
Pre-ART loss to care Multivariate logistic regression, 
adjusting for gender, age, marital 
status, and time from CD4 count 
to date of ART training 
Adjusted odds ratios (95% CI):
Low baseline CD4 (≤100): 2.13 
(1.22, 3.71)
Unemployed: 1.88 (1.09, 3.23)
16.4% lost to care before ART
Those lost pre-ART were more 
likely to be male, unemployed 
and a baseline CD4 below 100.
4 Fairall LR, Bachmann MO, Louwagie 
GM, van Vuuren C, Chikobvu P, Steyn 
D, Staniland GH, Timmerman V, 
Msimanga M, Seebregts CJ, Boulle A, 
Nhiwatiwa R, Bateman ED, 
Zwarenstein MF, Chapman RD. 
Effectiveness of antiretroviral 
treatment in a South African 
program: a cohort study. Arch Intern 
Med. 2008 Jan 14;168(1):86-93.  
2008 Free State 
province, 
South Africa
14267 patients 
(age ≥16) 
enrolled in 
public-sector 
treatment 
program
Observational 
cohort with 
repeated 
measures
Up to 20 
months
Not starting ART 
when eligible
Baseline 
characteristics, 
started ART or CPT, 
and months since 
starting ART
Death, incident TB, 
change in CD4 count 
and weight
Marginal structural regression 
models to account for time-
varying covariates; Cox PH 
regression models of association 
between exposures and death  or 
incident TB
Of patients eligible by CD4, 45.3% 
started ART during the study 
period.  Of over 4500 patients 
followed for 1 year, 53.2% died, 
87% without receiving ART.
Article doesn't talk about patients 
LTFU, but found high rates of 
mortality and low rates of linkage 
to care.   Delays starting ART 
contribute to high mortality rates.
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5 Ingle SM, May M, Uebel K, 
Timmerman V, Kotze E, Bachmann M, 
Sterne JA, Egger M, Fairall L; IeDEA-
Southern Africa. Outcomes in 
patients waiting for antiretroviral 
treatment in the Free State Province, 
South Africa: prospective linkage 
study. AIDS. 2010 Nov 13;24(17):2717-
25.
2010 Free State 
province, 
South Africa
22,083 patients 
(age ≥15) 
enrolled in 
public-sector 
treatment 
program and 
eligible for ART 
(CD4≤ 200)
Observational 
cohort
Minimum 1 
year, 
maximum 4.5 
years
Not starting ART 
when eligible
Baseline 
characteristics (sex, 
age, weight, CD4 
count, year of 
enrollment, facility 
size, facility location, 
facility distance from 
home)
Time to starting 
treatment and time 
to pre-ART death
Competing risk framework used 
to estimate the cumulative 
incidence of starting ART (overall 
and stratified by CD4, competing 
risk: death), and also pre-ART 
death (competing risk: starting 
ART); competing risk Cox PH 
regression modeling 
(subdistribution hazard ratios) of 
association of patient and facility 
characteristics with starting ART 
and pre-ART, adjusting for 
baseline characteristics
86% of patients were eligible for 
ART at first CD4; After 2 years, 
among those eligible for 
treatment, 67.7% had started and 
26.2% had died before starting, 
6% were alive and untreated.  
Among those with baseline CD4 ≤ 
25, 48% died before ART and 51% 
started ART
High mortality among eligible 
patients waiting for ART; the most 
immunocompromised patients 
had the lowest probability of 
starting ART; unusually low rates 
of LTFU (not discussed at all in the 
paper)
6 Kaplan R, Orrell C, Zwane E, Bekker 
LG, Wood R. Loss to follow-up and 
mortality among pregnant women 
referred to a community clinic for 
antiretroviral treatment. AIDS. 2008 
Aug 20;22(13):1679-81.
2008 Gugulethu, 
South Africa
2131 ART-naïve 
women 
referred for 
ART, of whom 
318 (15%) were 
pregnant at 
time of 
screening
Observational 
cohort
3 years Percentage of 
patients 
referred for ART 
who refused 
treatment or did 
not return to the 
clinic
Preganant at the 
time of ART referral
LTFU and mortality 
during pre-ART 
period
Comparing proportions Women pregnant at ART referral 
were more likely to be LTFU than 
non-pregnant women  (13.2% vs 
6.0%, p<0.001) but motality was 
lower among pregnant women 
(0.3% vs 4.7%, p<0.001)
Pregnant women are at higher 
risk of LTFU during the pre-ART 
and post-ART periods, despite 
being at lower risk of mortality 
during these times.
This finding highlights the need 
for programmatic interventions to 
address retention in care for this 
patient population.
7 Kranzer K, Zeinecker J, Ginsberg P, 
Orrell C, Kalawe NN, Lawn SD, Bekker 
LG, Wood R. Linkage to HIV care and 
antiretroviral therapy in Cape Town, 
South Africa. PLoS One. 2010 Nov 
2;5(11):e13801.
2010 Cape Town, 
South Africa
988: random 
sample of 
adults testing 
HIV-positive 
through ANC, 
STI or VCT + all 
testing HIV-
positive 
through TB 
services
Observational 
cohort
5 years 1) "Linkage to 
HIV care": CD4 
result within 6 
mos of diagnosis
2) "Linkage to 
ART care" 
Initiated ART 
within 6 mos of 
HIV testing, if 
eligible (CD4 ≤ 
200)
Age, gender, year 
tested
Stratified all results 
by type of pt: ANC, 
STI, TB or VCT
Linkage to HIV care 
and linkage to ART 
care
Multivariate log-binomial 
regression, adjusting for 
covariates listed in Exposure 
category
62.6% received CD4 result w/in 6 
mos, highest among ANC and STI 
pts, lowest among VCT 
66.7% of eligible pts accessed ART 
care within 6 mos
Linkage to HIV care RR:
Tested in 2007-2009 (vs 2004-
2006): TB pts: 1.67 (95% CI: 1.27, 
2.21); VCT pts: 1.60 (95% CI: 1.40, 
1.84); ANC pts: 0.87 (95% CI: 0.74, 
0.99)
People who test on their own are 
less likely to have a timely CD4
TB patients did not receive 
concomitant HIV treatment
Men and younger adults were 
less likely to link to care overall
Linkage to care improved over 
more recent years
ANC pts more likely to link to ART 
care
8 Larson BA, Brennan A, McNamara L, 
Long L, Rosen S, Sanne I, Fox MP. 
Early loss to follow up after 
enrolment in pre-ART care at a large 
public clinic in Johannesburg, South 
Africa. Trop Med Int Health. 2010 
Jun;15 Suppl 1:43-7.
2010 Johannesburg, 
South Africa
356 patients 
newly enrolled 
in the pre-ART 
program and 
not yet eligible 
for ART
Observational 
cohort
13 months Failure to attend 
the first medical 
visit within 1 
year (scheduled 
for 6 mos after 
dx if CD4 >350 
and 3 mos after 
dx if CD4 251-
350)
Age, gender, 
employment, marital 
status, baseline CD4
Early LTFU Modified Poisson regression 
using robust standard errors
Adjusted RR for pt returning for 
first visit:
Employed: 1.41 (95% CI: 1.03, 
1.92)
CD4 351-450: 0.66 (95% CI: 0.46, 
0.96)
CD4 451+: 0.61 (95% CI: 0.42, 0.88)
Overall, 69% of pts didn't return 
for first medical visit within 1 
year: 74% of pts w/CD4 >350 and 
59% of pts with CD4 251-350
Less than 1/3 of HIV-positive 
patients enrolled in pre-ART care 
returned for their first medical 
visit within 1 year.
Pre-ART care is a "broken link" 
that should connect HIV testing to 
ART
Risk of returning was positively 
associated with being employed 
and negatively associated with 
higher baseline CD4
8
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Citation
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Sample 
size/population Study design
Follow-up 
period LTFU definition Exposure(s) Outcome(s) Statistical methods Results Conclusion
9 Larson BA, Brennan A, McNamara L, 
Long L, Rosen S, Sanne I, Fox MP. Lost 
opportunities to complete CD4+ 
lymphocyte testing among patients 
who tested positive for HIV in South 
Africa. Bull World Health Organ. 2010 
Sep 1;88(9):675-80.
2010 Johannesburg, 
South Africa
352 walk-in VCT 
clients who 
tested HIV-
positive
Observational 
cohort
12 weeks Failure to have 
CD4 test and 
collect result
Gender, age, marital 
status, employment 
status, baseline CD4
Pts collecting CD4 
result within 6 weeks 
and 12 weeks of 
diagnosis
Multivariate logistic regression, 
adjusted for gender, age, 
employment status, marital 
status and baseline CD4
35% overall completed CD4 
testing: 51.3% of patients eligible 
for ART completed CD4 testing 
within 12 wks; only 14.9% of 
patients not eligible (CD4>200) 
completed within 12 wks
The higher the baseline CD4 
count, the lower the odds of 
completing CD4 testing within 12 
weeks
Losing patients at the CD4 stage 
results in delayed ART care
10 Losina E, Bassett IV, Giddy J, Chetty S, 
Regan S, Walensky RP, Ross D, Scott 
CA, Uhler LM, Katz JN, Holst H, 
Freedberg KA. The "ART" of linkage: 
pre-treatment loss to care after HIV 
diagnosis at two PEPFAR sites in 
Durban, South Africa. PLoS One. 2010 
Mar 4;5(3):e9538.
2010 Durban, South 
Africa
454 adult (≥18) 
patients newly 
testing HIV-
positive
Observational 
cohort
8 weeks "PTLC" (pre-
treatment loss 
to care): Failure 
to have a CD4 
count within 8 
weeks of HIV 
diagnosis
Distance ≥10 km from 
home to clinic, 
history of TB 
treatment, self-
referral vs. medical 
referral for HIV test
PTLC Multivariate log-linear regression 
modeling, adjusted for covariates 
listed in Exposure category
45% PTLC overall
Lived ≥10 km from clinic: RR 1.37 
(95% CI: 1.11, 1.71)
History TB treatment: RR 1.26 
(95% CI: 1.00, 1.58)
Medical referral: RR 1.61 (95% CI: 
1.22, 2.13)
21% of those PTLC had none of 
these risk factors
Nearly half of pts failed to have 
CD4 counts after diagnosis
11 Rosen S, Fox MP. Retention in HIV 
Care between Testing and Treatment 
in Sub-Saharan Africa: A Systematic 
Review. PLoS Med. 2011 July; 8(7): 
e1001056. 
2011 Sub-Saharan 
Africa (7 
countries)
28 studies Systematic 
review
Varied Failing to reach 
the next step in 
the care 
sequence for 
any reason 
(including 
death)
--- Median proportion of 
patients completing 
each stage of the pre-
ART process: 1) 
testing positive to 
completing CD4 
staging, 2) if not 
eligible for ART, pre-
ART care to eligibility 
for ART, 3) ART 
eligibility to 
beginning ART
When possible, calculated 95% Ci 
for proportion of pts retained or 
linked; grouped the findings into 
the 3 stages and illustrated 
results using forest plots; 
estimated the median proportion 
of pts completing each stage and 
reported the median and range
Median (range) retained at each 
stage: 
Stage 1: 59% (35% - 88%)
Stage 2: 46% (31%-95%)
Stage 3: 68% (14%-84%)
Multiplying the 3 medians: 18%
Substantial LTFU at every stage of 
pre-ART care
Need to look at the proportion of 
pts who complete all stages 
within a single setting
Need to report results up to a 
clinically meaningful end point 
within a stage, not just to the 
point of censoring
12 Tayler-Smith K, Zachariah R, 
Massaquoi M, Manzi M, Pasulani O, 
van den Akker T, Bemelmans M, 
Bauernfeind A, Mwagomba B, Harries 
AD. Unacceptable attrition among 
WHO stages 1 and 2 patients in a 
hospital-based setting in rural 
Malawi: can we retain such patients 
within the general health system? 
Trans R Soc Trop Med Hyg. 2010 
May;104(5):313-9. 
2010 Thyolo District 
(rural), Malawi
1,633 adults in 
WHO stages 1 
and 2
Observational 
cohort
Minimum 1 
month, 
maximum 13 
months
One month or 
more from last 
scheduled visit
Starting ART or not 
starting ART (in 
Malawi, only patients 
on ART are traced 
after defaulting)
Alive, dead, LTFU, 
transferred facilities
K-M estimates of cumulative 
incidences of attrition (death and 
LTFU and stopping treatment); 
Cox PH regression modeling of 
the association between 
starting/not starting ART and 
attrition and LTFU
Attrition rates were 31 times 
higher among pre-ART group vs 
ART group, after adjusting for age, 
sex and baseline CD4 (adjusted 
HR: 31.0, 95% CI: 21.9, 44.0)
Of the 824 patients lost prior to 
ART, 95% were lost prior to 
getting their CD4 count and first 
counseling appt (2-4 weeks after 
registration)
Very high early LTFU among pre-
ART patients
Nearly all pre-ART patients LTFU 
were lost within 2-4 weeks, which 
was before CD4 staging
Pre-ART patients were managed 
differently, followed-up 
differently, and used different 
facilities (outpatient vs. ART-
specialized clinic)
8
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Table A.3. Summary table of early ART initiation literature 
Citation
Year 
published Location
Sample 
size/population Study design
Follow-up 
period LTFU definition Exposure(s) Outcome(s) Statistical methods Results Conclusion
1 Ford N, Kranzer K, Hilderbrand K, 
Jouquet G, Goemaere E, Vlahakis N, 
Triviño L, Makakole L, Bygrave H. 
Early initiation of antiretroviral 
therapy and associated reduction in 
mortality, morbidity and defaulting 
in a nurse-managed, community 
cohort in Lesotho. AIDS. 2010 Nov 
13;24(17):2645-50.
2010 Lesotho 1177 Prospective, 
observational 
cohort
Minimum 1 
year, 
maximum 2 
years
Missing an apt 
for more than 90 
days
Baseline CD4 count: 
early initiation (200 - 
350) vs late (<200, 
ref.)
Mortality, morbidity, 
LTFU and 
hospitalization
K-M estimates to describe 
cumulative probability of 
progression to outcome; Cox PH 
regression modeling to estimate 
HR (adjusting for sex, age, 
pregnant at initiation, TB at 
initiation and migrant worker 
Y/N); possible misclassification of 
mortality assessed through 
sensitivity analysis using 
competing risks framework
Adjusted HR (95% CI):
Mortality: 0.32 (0.20, 0.50)
LTFU: 0.61 (0.43, 0.87)
Incident morbidity:
0.73 (0.65, 0.82)
Hospitalization:
0.37 (0.19, 0.73)
Early initiation is feasible and 
reduces mortality, morbidity, 
LTFU and hospitalization
2 Fox MP, Sanne IM, Conradie F, 
Zeinecker J, Orrell C, Ive P, Rassool 
M, Dehlinger M, van der Horst C, 
McIntyre J, Wood R.  Initiating 
patients on antiretroviral therapy at 
CD4 cell counts above 200 
cells/microl is associated with 
improved treatment outcomes in 
South Africa. AIDS. 2010 Aug 
24;24(13):2041-50.
2010 Johannesburg 
and Cape 
Town, South 
Africa
812 Observational 
cohort; part of 
unblinded RCT
Minimum 2 
years, median 
27.5 months
Missing 3 or 
more 
consecutive 
study visits
Baseline CD4 count: 
early initiation (200 - 
350, ref.) vs late 
(<200)
Treatment failure, 
incident TB and 
program failure
K-M estimates of the rate of 
treatment failure by baseline 
CD4; Cox PH regression modeling 
(adjusting for age, sex [stratified 
at baseline into men, pregnant 
women and non-pregnant 
women], study site and 
randomization group).  Dose 
response model with finer 
categorizations of baseline CD4.  
Explored interaction of CD4 with 
baseline immunosuppression 
markers (VL, WHO stage, BMI, etc)
Adjusted HR (95% CI):
Death/virologic failure: 1.9 (1.1, 
3.3)
Incident TB: 1.9 (0.89, 4.04)
LTFU: 0.79 (0.50, 1.25)
Initiating ART early results in 
reduced mortality, TB and less 
virologic failure.  CD4 cell count 
eligibility criteria should be 
increased.
3 Mills EJ, Bakanda C, Birungi J, 
Mwesigwa R, Chan K, Ford N, Hogg 
RS, Cooper C. Mortality by baseline 
CD4 cell count among HIV patients 
initiating antiretroviral therapy: 
evidence from a large cohort in 
Uganda. AIDS. 2011 Mar 27;25(6):851-
5.
2011 10 clinics 
throughout 
Uganda
22,315 patients 
≥14 years 
initiating ART
Observational 
cohort
Median: 31 
months
3 month 
untraceable 
absence from a 
clinic
Baseline CD4: (<50, 
50-99, 100-149, 150-
199, 200-249, 250-299, 
≥300)
Mortality K-M estimates of survival by 
baseline CD4; weighted analysis 
where 30% of LTFU patients were 
assumed dead, weighted by 
baseline CD4, age and male sex; 
Cox PH regression modeling of 
association between baseline 
CD4 and mortality, adjusting for 
age, sex and WHO clinical stage
6.7% of patients died and 6.4% 
were LTFU; mortality highest 
within first year and among 
patients with CD4 <50
Compared to baseline CD4 <50, 
CD4 ≥250, HR of mortality: 0.41 
(95% CI: 0.33, 0.51)
Initiating ART late is associated 
with reduced survival time; 
decreased baseline CD4 is a 
strong predictor of mortality
Early initiation appears to reduce 
mortality and also may offer 
fewer co-infections, lower 
resource costs and possibly 
prevention
Sites involved in this study 
employ a mobile tracing team, so 
rates of LTFU were low
4 Severe P, Juste MA, Ambroise A, 
Eliacin L, Marchand C, Apollon S, 
Edwards A, Bang H, Nicotera J, 
Godfrey C, Gulick RM, Johnson WD Jr, 
Pape JW, Fitzgerald DW. Early versus 
standard antiretroviral therapy for 
HIV-infected adults in Haiti. N Engl J 
Med. 2010 Jul 15;363(3):257-65.
2010 Port au Prince, 
Haiti
816 RCT Median: 21 
months
None, and field 
workers visited 
patients at home 
to ensure 
retention
Early initiation (CD4 
201-349) vs. standard 
initiation (≤200)
Primary: Survival
Secondary: incident 
TB
K-M estimates of survival by 
study arm; log-rank test to 
evaluate the survival curves; Cox 
PH regression modeling
Adjusted HR (95% CI):
Death w/standard therapy: 4.0 
(1.6, 9.8)
Incident TB w/standard therapy: 
2.0 (1.2, 3.6)
When ART is initiated earlier in a 
resource-poor area, a 75% 
reduction in the rate of death and 
a 50% decrease in the incidence 
of TB was found.  Access to ART 
should be expanded in resource-
poor areas.
8
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